WO2003061567A2 - Selective s1p1/edg1 receptor agonists - Google Patents

Selective s1p1/edg1 receptor agonists Download PDF

Info

Publication number
WO2003061567A2
WO2003061567A2 PCT/US2003/001120 US0301120W WO03061567A2 WO 2003061567 A2 WO2003061567 A2 WO 2003061567A2 US 0301120 W US0301120 W US 0301120W WO 03061567 A2 WO03061567 A2 WO 03061567A2
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
edgl
slp3
edg3
compound
Prior art date
Application number
PCT/US2003/001120
Other languages
French (fr)
Other versions
WO2003061567A3 (en
Inventor
George A. Doherty
Michael J. Forrest
Richard Hajdu
Jeffrey J. Hale
Zhen Li
Suzanne M. Mandala
Sander G. Mills
Hugh Rosen
Edward M. Scolnick
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA002472680A priority Critical patent/CA2472680A1/en
Priority to EP20030731917 priority patent/EP1469863A2/en
Priority to AU2003216054A priority patent/AU2003216054B2/en
Priority to US10/501,176 priority patent/US20050070506A1/en
Publication of WO2003061567A2 publication Critical patent/WO2003061567A2/en
Publication of WO2003061567A3 publication Critical patent/WO2003061567A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.

Description

TITLE OF THE INVENTION
SELECTIVE S1P1/EDG1 RECEPTOR AGONISTS
BACKGROUND OF THE INVENTION The present invention is related to compounds that are selective
SlPl/Edgl receptor agonists and thus have immunosuppressive activities by producing lymphocyte sequestration in secondary Iymphoid tissues. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention. Immunosuppressive agents have been shown to be useful in a wide variety of autoimmune and chronic inflammatory diseases, including systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy, atopic dermatitis and asthma. They have also proved useful as part of chemotherapeutic regimens for the treatment of cancers, lymphomas and leukemias.
Although the underlying pathogenesis of each of these conditions may be quite different, they have in common the appearance of a variety of autoantibodies and/or self -reactive lymphocytes. Such self-reactivity may be due, in part, to a loss of the homeostatic controls under which the normal immune system operates. Similarly, following a bone-marrow or an organ transplantation, the host lymphocytes recognize the foreign tissue antigens and begin to produce both cellular and humoral responses including antibodies, cytokines and cytotoxic lymphocytes which lead to graft rejection.
One end result of an autoimmune or a rejection process is tissue destruction caused by inflammatory cells and the mediators they release. Anti- inflammatory agents such as NSAIDs act principally by blocking the effect or secretion of these mediators but do nothing to modify the immunologic basis of the disease. On the other hand, cytotoxic agents, such as cyclophosphamide, act in such a nonspecific fashion that both the normal and autoimmune responses are shut off. Indeed, patients treated with such nonspecific immunosuppressive agents are as likely to succumb to infection as they are to their autoimmune disease. Cyclosporin A is a drug used to prevent rejection of transplanted organs. FK-506 is another drug approved for the prevention of transplant organ rejection, and in particular, liver transplantation. Cyclosporin A and FK-506 act by inhibiting the body's immune system from mobilizing its vast arsenal of natural protecting agents to reject the transplant's foreign protein. Cyclosporin A was approved for the treatment of severe psoriasis and has been approved by European regulatory agencies for the treatment of atopic dermatitis.
Though they are effective in delaying or suppressing transplant rejection, Cyclosporin A and FK-506 are known to cause several undesirable side effects including nephrotoxicity, neurotoxicity, and gastrointestinal discomfort. Therefore, an immunosuppressant without these side effects still remains to be developed and would be highly desirable.
The immunosuppressive compound FTY720 is a lymphocyte sequestration agent currently in clinical trials. FTY720 is metabolized in mammals to a compound that is a potent agonist of sphingosine 1-phosphate receptors. Agonism of sphingosine 1-phosphate receptors induces the sequestration of lymphocytes (T-cells and B-cells) in lymph nodes and Peyer's patches without lymphodepletion. Such immunosuppression is desirable to prevent rejection after organ transplantation and in the treatment of autoimmune disorders. Sphingosine 1-phosphate is a bioactive sphingolipid metabolite that is secreted by hematopoietic cells and stored and released from activated platelets. Yatomi, Y., T. Ohmori, G. Rile, F. Kazama, H. Okamoto, T. Sano, K. Satoh, S. Kume, G. Tigyi, Y. Igarashi, and Y. Ozaki. 2000. Blood. 96:3431-8. It acts as an agonist on a family of G protein-coupled receptors to regulate cell proliferation, differentiation, survival, and motility. Fukushima, N., I. Ishii, J.J.A. Contos, J.A. Weiner, and J. Chun. 2001. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:507-34; HQa, T., M.-J. Lee, N. Ancellin, J.H. Paik, and M.J. Kluk. 2001. Lysophospholipids - Receptor revelations. Science. 294:1875-1878; Spiegel, S., and S. Milstien. 2000. Functions of a new family of sphingosine- 1-phosphate receptors. Biochim. Biophys. Acta. 1484:107-16; Pyne, S., and N. Pyne. 2000. Sphingosine 1- phosphate signalling via the endothelial differentiation gene family of G-protein coupled receptors. Pharm. & Therapeutics. 88:115-131. Five sphingosine 1- phosphate receptors have been identified (SlPi, S1P2, SIP3, SIP4, and SIP5, also known as endothelial differentiation genes Edgl, Edg5, Edg3, Edg6, Edg8), that have widespread cellular and tissue distribution and are well conserved in human and rodent species (see Table). Binding to SIP receptors elicits signal transduction through Gq-, Gi/o, G12-, G13-, and Rho-dependent pathways. Ligand-induced activation of SlPi and SIP3 has been shown to promote angiogenesis, chemotaxis, and adherens junction assembly through Rac- and Rho-, see Lee, M.-J., S. Thangada, K.P. Claffey, N. Ancellin, CH. Liu, M. Kluk, M. Volpi, R.I. Sha'afi, and T. Hla.
1999. Cell. 99:301-12, whereas agonism of SIP2 promotes neurite retraction, see Van
Brocklyn, J.R., Z. Tu, L.C. Edsall, R.R. Schmidt, and S. Spiegel. 1999. /. Biol. Chem. 274:4626-4632, and inhibits chemotaxis by blocking Rac activation, see Okamoto, H.,
N. Takuwa, T. Yokomizo, N. Sugimoto, S. Sakurada, H. Shigematsu, and Y. Takuwa.
2000. Mol. Cell. Biol. 20:9247-9261. SIP4 is localized to hematopoietic cells and tissues, see Graeler, M.H., G. Bernhardt, and M. Lipp. 1999. Curr. Top. Microbiol. Immunol. 246:131-6, whereas SIP5 is primarily a neuronal receptor with some expression in Iymphoid tissue, see Im, D.S., C.E. Heise, N. Ancellin, B.F. ODowd, GJ. Shei, R.P. Heavens, M.R. Rigby, T. HJa, S. Mandala, G. McAllister, S.R. George, and K.R. Lynch. 2000. J. Biol. Chem. 275:14281-6. Administration of sphingosine 1- phosphate to animals induces systemic sequestration of peripheral blood lymphocytes into secondary Iymphoid organs, stimulates FGF-mediated blood vessel growth and differentiation, see Lee, et al., supra, but also has cardiovascular effects that limit the utility of sphingosine 1-phosphate as a therapeutic agent, see Sugiyama, A., N.N. Aye, Y. Yatomi, Y. Ozaki, and K. Hashimoto. 2000. Jpn. J. Pharmacol. 82:338-342. The reduced heart rate and blood pressure measured with sphingosine 1-phosphate is associated with its non-selective, potent agonist activity on all SIP receptors. The present invention is directed towards compounds which are selective agonists of the SlPl/Edgl receptor while having the specified window of selectivity as agonists of, or alternately antagonists or inverse agonists of the SlP3/Edg3 receptor. An SlPl/Edgl receptor selective agonist has advantages over current therapies and extends the therapeutic window of lymphocytes sequestration agents, allowing better tolerability with higher dosing and thus improving efficacy as monotherapy. Receptor agonists selective for SlPl/Edgl over SlP3/Εdg3 having enhanced cardiovascular tolerability in rats are exemplified. While the main use for immunosuppressants is in treating bone marrow, organ and transplant rejection, other uses for such compounds include the treatment of arthritis, in particular, rheumatoid arthritis, insulin and non-insulin dependent diabetes, multiple sclerosis, psoriasis, inflammatory bowel disease, Crohn's disease, lupus erythematosis and the like.
Thus, the present invention is focused on providing immunosuppressant compounds that are safer and more effective than prior compounds. These and other objects will be apparent to those of ordinary skill in the art from the description contained herein.
Figure imgf000005_0001
SUMMARY OF THE INVENTION The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPl/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the SlPl/Edgl receptor and which possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPl/Edgl receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor.
DETAILED DESCRIPTION OF THE INVENTION
The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPl/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl Edgl receptor over the S 1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the S IPl Edgl receptor to the EC50 for the S lP3 Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPl/Edgl receptor of 100 nM or less as evaluated by the
35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000006_0001
A or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Ci-4alkyl or haloCi_4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci-4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4alkyl, O-haloCι_4alkyl or hydroxyCι_4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4-I4alkyl and C4_i4alkenyl.
An embodiment of the invention encompasses the above method wherein the compound has a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S lP3/Εdg3 receptor as evaluated in the 35s-
GTPγS binding assay.
Another embodiment of the invention encompasses the above method wherein the compound has a selectivity for the SlP /Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-
GTPγS binding assay.
Another embodiment of the invention encompasses the above method wherein the compound has a selectivity for the S IPi/Edgl receptor over the S lP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Εdg3 receptor as evaluated in the 35s-
GTPγS binding assay.
Another embodiment of the invention encompasses the above method wherem the compound has a selectivity for the SlPl/Edgl receptor over the . SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3 Edg3 receptor as evaluated in the 5s-
GTPγS binding assay.
The invention also encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPl/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S lP3/Εdg3 receptor as evaluated in the 35s~GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPl/Edgl receptor of 10 nM or less as evaluated by the 35s-
GTPγS binding assay.
Within this embodiment is encompassed the above method wherein the compound possesses an EC50 for binding to the S IPl/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPl/Edgl receptor over the S lP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay.
Also within this embodiment is encompassed the above method wherem the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the S 1PR3/Edg3 receptor as evaluated in the 35S-GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi/Edgl receptor over the S 1PR3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 5s- GTPγS binding assay.
The invention also encompasses a pharmaceutical composition comprised of a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Εdg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the S IPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000010_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Ci_4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci_4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4alkyl, O-haloCι_4alkyl or hydroxyCi_4alkyl,
Y is selected from the group consisting of: -CEfc-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl, in combination with a pharmaceutically acceptable earner.
The present invention also encompasses a pharmaceutical composition comprised of a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 10 nM or less as evaluated by the 35s-GTPγS binding assay, in combination with a pharmaceutically acceptable carrier.
For purposes of this specification, when a compound is said to be evaluated by the 35s-GTPγS binding assay, this means said compound is evaluated following the procedures described herein under the heading 35s-GTPγS binding assay. The present invention is directed towards compounds which are selective agonists of the SlPl/Edgl receptor while having the specified window of selectivity as agonists of, or alternately antagonists or inverse agonists of the SlP3/Edg3 receptor. The invention also encompasses compounds that are agonists of the SlPl/Edgl receptor while having the specified window of selectivity as non- modulators of the S lP3/Edg3 receptor.
A further embodiment of the invention encompasses the concomitant administration of an SlPl/Edgl receptor in combination with an antagonist or inverse agonist of the S lP3/Εdg3 receptor, such that the combined therapy possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPl/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
The invention also encompasses the above method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.
The invention also encompasses the above method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft- versus-host disease.
The invention also encompasses the above method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, chronic lymphocytic leukemia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia- reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection. The invention also encompasses the above method wherein the immunoregulatory abnormality is multiple sclerosis.
The invention also encompasses the above method wherein the immunoregulatory abnormality is rheumatoid arthritis.
The invention also encompasses the above method wherein the immunoregulatory abnormality is systemic lupus erythematosus.
The invention also encompasses the above method wherein the immunoregulatory abnormality is psoriasis. The invention also encompasses the above method wherein the immunoregulatory abnormality is rejection of transplanted organ or tissue.
The invention also encompasses the above method wherein the immunoregulatory abnormality is inflammatory bowel disease.
The invention also encompasses the above method wherein the immunoregulatory abnormality is a malignancy of Iymphoid origin, such as acute and chronic lymphocytic leukemias and lymphomas.
Exemplifying the invention are the following compounds, which possess a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and which possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay:
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Further exemplifying the invention are the following compounds, which possess a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and which possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay:
Figure imgf000018_0002
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
The invention is described using the following definitions unless otherwise indicated.
The term "halogen" or "halo" includes F, Cl, Br, and I.
The term "alkyl" means linear or branched structures and combinations thereof, having the indicated number of carbon atoms. Thus, for example, Ci-βalkyl includes methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1- dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cydohexyl.
The term "haloalkyl" means alkyl as defined above substituted with at least one halo group, as defined above, and being optionally substituted with halo up to the maximum number of substituable positions. The term "hydroxyalkyl" means alkyl as defined above substituted with at least one hydroxy group, and being optionally substituted with hydroxyup to the maximum number of substituable positions.
The term "alkoxy" means alkoxy groups of a straight, branched or cyclic configuration having the indicated number of carbon atoms. Cι_6alkoxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.
The term "alkylthio" means alkylthio groups having the indicated number of carbon atoms of a straight, branched or cyclic configuration. Cι_ 6alkylthio, for example, includes methylthio, propylthio, isopropylthio, and the like. The term "alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen may be replaced by an additional carbon-to-carbon double bond. C2-6alkenyl, for example, includes ethenyl, propenyl,
1-methylethenyl, butenyl and the like. The term "alkynyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon triple bond. C3_6alkynyl, for example, includes , propenyl, 1- methylethenyl, butenyl and the like.
The term "HET" is defined as a 5- to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, containing 1-5 heteroatoms selected from O, S and N, and optionally substituted with 1-2 oxo groups. Preferably, "HET" is a 5- or 6-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N, for example, pyridine, pyrimidine, pyridazine, furan, thiophene, thiazole, oxazole, isooxazole and the like, or heterocycle is a 9- or 10-membered aromatic or partially aromatic bicyclic ring containing 1-3 heteroatoms selected from O, S, and N, for example, benzofuran, benzothiophene, indole, pyranopyrrole, benzopyran, quionoline, benzocyclohexyl, naphtyridine and the like. "HET" also includes the following: benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyiTolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl.
A preferred group of HET is as follows:
Figure imgf000030_0001
The term "treating" encompasses not only treating a patient to relieve the patient of the signs and symptoms of the disease or condition but also prophylactically treating an asymptomatic patient to prevent the onset or progression of the disease or condition. The term "amount effective for treating" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. The term also encompasses the amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
The invention described herein includes pharmaceutically acceptable salts and hydrates. Pharmaceutically acceptable salts include both the metallic (inorganic) salts and organic salts; a list of which is given in Remington's Pharmaceutical Sciences, 17th Edition, pg. 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowability, hydroscopicity and solubility. As will be understood by those skilled in the art, pharmaceutically acceptable salts include, but are not limited to salts of inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate or salts of an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate or pamoate, salicylate and stearate. Similarly pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium (especially ammonium salts with secondary amines). Preferred salts of this invention for the reasons cited above include potassium, sodium, calcium and ammonium salts. Also included within the scope of this invention are crystal forms, hydrates and solvates of the compounds of the present invention.
For purposes of this Specification, "pharmaceutically acceptable hydrate" means the compounds of the instant invention crystallized with one or more molecules of water to form a hydrated form.
The invention also includes the compounds falling within the present invention in the form of one or more stereoisomers, in substantially pure form or in the form of a mixture of stereoisomers. All such isomers are encompassed within the present invention.
The compounds disclosed herein are selective agonists of the SlPl/Edgl receptor while having the specified window of selectivity as agonists of, or alternately antagonists or inverse agonists of the SlP3/Edg3 receptor. An Edgl selective agonist has advantages over current therapies and extends the therapeutic window of lymphocytes sequestration agents, allowing better tolerability of higher dosing and thus improving efficacy as monotherapy. The compounds disclosed herein are useful to suppress the immune system in instances where immunosuppression is in order, such as in bone marrow, organ or transplant rejection, autoimmune and chronic inflammatory diseases, including systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.
More particularly, the compounds disclosed herein are useful to treat or prevent a disease or disorder selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non- A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.
Also embodied within the present invention is a method of preventing or treating resistance to transplantation or transplantation rejection of organs or tissues in a mammalian patient in need thereof, which comprises administering a therapeutically effective amount of the compounds of the present invention. A method of suppressing the immune system in a mammalian patient in need thereof, which comprises administering to the patient an immune system suppressing amount of the compounds of the present invention is yet another embodiment.
Most particularly, the method described herein encompasses a method of treating or preventing bone marrow or organ transplant rejection which is comprised of admininstering to a mammalian patient in need of such treatment or prevention a compound of the present invention, or a pharmaceutically acceptable salt or hydrate thereof, in an amount that is effective for treating or preventing bone marrow or organ transplant rejection.
A pharmaceutical formulation of the present invention comprises a pharmaceutically acceptable canier and a compound disclosed herein or a pharmaceutically acceptable salt or hydrate thereof. A preferred embodiment of the formulation is one where a second immunosuppressive agent is also included. Examples of such second immunosuppressive agents are, but are not limited to azathioprine, brequinar sodium, deoxyspergualin, mizaribine, mycophenolic acid morpholino ester, cyclosporin, FK-506, rapamycin and FTY720. The present compounds, including salts and hydrates thereof, are useful in the treatment of autoimmune diseases, including the prevention of rejection of bone marrow transplant, foreign organ transplants and/or related afflictions, diseases and illnesses.
The compounds disclosed herein can be administered by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration, can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravaginal, rectal, intracisternal and parenteral. The term "parenteral" as used herein refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrasternal and intraperitoneal.
The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 0.1-2000 milligrams per day. Ordinaiily, from 1 to 100 milligrams per day in one or more applications is effective to obtain desired results. These dosages are the effective amounts for the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions. The active ingredient can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal .tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
For administration by inhalation, the compounds disclosed herein may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of the present invention in suitable propellants, such as fluorocarbons or hydrocarbons.
For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of the present invention in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:
CAPSULES A large number of unit capsules are prepared by filling standard two- piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
SOFT GELATIN CAPSULES A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.
TABLETS A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
INJECTABLE A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized. SUSPENSION
An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
The same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction with another therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus the term coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components.
Methods for preparing the compounds of this invention are illustrated in the following schemes and examples. Alternative routes will be easily discernible to practitioners in the field.
In the tables that follow, any NMR data follows the compounds:
PREPARATION OF N-BENZYL PYRROLIDINE AND N-BENZYL AZETIDINE CARBOXYLATES, PHOSPHINATES AND PHOSPHANATES
Examples I-LVIII have the following structures:
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
GENERAL
Concentration of solutions was carried out on a rotary evaporator under reduced pressure. Conventional flash chromatography was carried out on silica gel (230-400 mesh). Flash chromatography was also carried out using a Biotage Flash
Chromatography apparatus (Dyax Corp.) on silica gel (32-63 mM, 60 A pore size) in pre-packed cartridges of the size noted. NMR spectra were obtained in CDC13 solution unless otherwise noted. Coupling constants (J) are in hertz (Hz). Abbreviations: diethyl ether (ether), triethylamine (TEA), N,N-diisopiOpylethylamine (DIEA) sat'd aqueous (sat'd), rt (rt), hour(s) (h), minute(s) (min). HPLC CONDITIONS LC-1: Waters Xterra MS C18, 5 μ, 4.6 x 50 mm column, 10:90 to 95:5 v/v CH3CN/H2O + 0.05% TFA over 4.5 min, hold 1 min, PDA detection 200-600 nm, flow rate = 2.5 mL/min.
LC-2: Analytical Sales and Service Armor C8 5 μ 20 x 100 mm column, 10:90 to 90:10 v/v CH3CN/H2O + 0.05% TFA over 12 min, hold 4 min, UV detection at either
210 or 254 nM, flow rate = 10 mL/min.
PREPARATION OF ALDEHYDE INTERMEDIATES
Aldehyde I 4-Nonylbenzaldehyde
A solution of 2.0 g (7.5 mmol) of 4-nonylbenzoyl chloride in 75 mL of THF at -78 oc was treated with 7.5 mL (7.5 mmol) of IM lithium tri-(tert-butoxy) aluminum hydride in THF. After 30 min at -78 °C, the reaction was quenched with 2N HCl and was allowed to warm to rt. The mixture was poured into Et2θ and washed with 2N HCl, sat'd NaHCO3 and sat'd NaCl. The organic layer was dried over MgSO4 and concentrated. The residue was purified on a 40M Biotage column using 100:1 v/v hexane/Et2θ as the eluant to afford 708 mg (41%) of the title compound: 1H-NMR (500 MHz) 60.87 (t, J = 7.0, 3H), 1.26-1.31 (m, 12H), 1.60- 1.66 (m, 2H), 2.68 (t, J = 7.8, 2H), 7.32 (d, J = 8.0, 2H), 7.79 (d, J = 8.0, 2H), 9.97 (s, IH).
Aldehyde π 4-Decylbenzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde II substituting 4-decylbenzoyl chloride for 4-nonylbenzoyl chloride: lH- NMR (500 MHz) δ 0.87 (t, J = 6.9, 3H), 1.25-1.31 (m, 14H), 1.60-1.66 (m, 2H), 2.68 (t, J = 7.7, 2H), 7.33 (d, J = 8.0, 2H), 7.79 (d, J = 8.0, 2H), 9.97 (s, IH). Aldehyde HI 3 - (Octyloxy)benzal dehyde
A mixture of 1.00 g (0.82 mmol) of 3-hydroxybenzaldehyde, 1.70 g (12.2 mmol) of potassium carbonate and 2.16 g (9.00 mmol) of 1-iodooctane were wanned in acetonitrile at 80 °C for 16 h. The reaction was cooled, filtered and concentrated. The residue was purified using flash chromatography using 20:1 v/v hexane/ethyl acetate to afford 1.63 g of the title compound as a colorless oil: iH-NMR (500 MHz) δ 0.89 (t, J = 6.9, 3H), 1.24-1.39 (m, 8H), 1.42-1.50 (m, 2H), 1.80 (m, 2H), 4.01 (t, J = 6.6, 2H), 7.19 (m, IH), 7.40 (s, IH), 7.44-7.46 (m, 2H), 9.99 (s, IH).
Aldehyde IV 4-(Octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde HI substituting 4-hydroxybenzaldehyde for 3-hydroxybenzaldehyde: iH NMR (500 MHz) δ 0.91 (t, J = 6.9, 3H), 1.29-1.41 (m, 8H), 1.46-1.52 (m, 2H), 1.71- 1.86 (m, 2H), 4.06 (t, J = 6.6, 2H), 7.01 (d, J = 8.7, 2H), 7.85 (d, J = 8.7, 2H), 9.90 (s, IH).
Aldehyde V 3-Bromo-5-methoxy-4-octyloxybenzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde IH substituting 3-bromo-4-hydroxy-5-methoxybenzaldehyde for 3- hydroxybenzaldehyde: ESI-MS: 343 (M+H)
Aldehyde VI
3-Ethoxy-4-(octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to
Aldehyde m substituting 3-ethoxy-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde: iH-NMR (500 MHz) δ 0.88-0.98 (m, 3H), 1.30-1.41 (m, 8H), 1.46-1.51 (m, 5H), 1.85-1.91 (m, 2H), 4.06-4.18 (m, 4H), 6.97 (d, J = 8.0, IH), 7.39-
7.44 (m, 2H), 9.84 (s, IH); ESI-MS 279.1 (M+H).
Aldehyde VH 3,5-Dibromo-4-(octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde UJ substituting 3,5-dibromo-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde.
Aldehyde Vm 3-Methoxy-4-(octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde HI substituting 3-methoxy-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde: ESI-MS 265.2 (M+H)
Aldehyde IX 3 -Methyl-4- (octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde UI substituting 3-methyl-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde.
Aldehyde X 4-(Octyloxy)- 1 -naphthaldehyde The title compound was prepared using a procedure analogous to
Aldehyde HI substituting 4-hydroxy-l-naphthaldehyde for 3-hydroxybenzaldehyde.
Aldehyde XI 2-Chloro-4-(octyloxy)benzaldehyde The title compound was prepared using a procedure analogous to
Aldehyde HI substituting 2-chloro-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde: ESI-MS 269.0 (M+H)
Aldehyde XH 3-Chloro-4-(octyloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde HI substituting 3-chloro-4-hydroxybenzaldehyde for 3- hydroxybenzaldehyde. Aldehyde XIH 4-(traπs,-3,7-Dimethyl-2,6-octadien-l-yloxy)benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde UJ using 4-hydroxybenzaldehyde and geranyl bromide: RF: 0.29 (19:1 v/v hexane/EtOAc); iH-NMR (500 MHz) δ 1.58-1.83 (m, 9H), 2.00-2.16 (m, 4H), 4.65 (d, J = 6.6, 2H), 5.10 (m, IH), 5.50 (m, IH), 7.02 (d, J = 8.7, 2H), 7.85 (d, J = 8.7, 2H), 9.90 (s, IH).
Aldehyde XIV
4- [Bis (3 ,5 -trifluoromethyl)benzyloxy]benzaldehyde
The title compound was prepared using a procedure analogous to Aldehyde HI using 4-hydroxybenzaldehyde and bis(3,5-trifluoiOmethyl)benzyl bromide: RF: 0.28 (9:1 v/v hexane/EtOAc); lH-NMR (500 MHz) δ 5.28 (s, 2H), 7.14 (d, J = 8.7, 2H), 7.91-7.95 (m, 5H), 9.95 (s, IH).
Aldehyde XV 3-(4-(Formyl)phenyl)-5-(4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4-oxadiazole
Step A: (E/Z)-2-Phenyl-3-chloro-4A4-trifluoro-2-butanal
Phosphorous oxychloride (7.5 mL, 80 mmol) was added to 15 mL of DMF at 0 °C. The resulting mixture was warmed to rt and stined for 1 h. A solution of 5.0 g (26.6 mmol) of l,l,l-trifluoromethyl-3-phenyl-2-propanone in 1 mL of DMF was added and the resulting mixture was stirred at 70 °C for 20 h. The reaction mixture was cooled to rt, poured onto 150 g of ice and stined at ambient temperature for 1 h. The quenched mixture was extracted with 200 mL of ether. The extract was washed with 200 mL of water, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (4L) as the eluant afforded 5.1 g (82%) of the title compound.
Step B: Ethyl (4-phenyl-5-trifluoromethyl thiophene-2-carboxylate Ethyl mercaptoacetate (2.75 mL, 25.0 mmol) was added to a suspension of 600 mg (25 mmol) of NaH in 45 mL of THF maintaining the intemal temperature at 25 °C. A solution of 5.10 g (21.7 mmol) of (E/Z)-2-phenyl-3-chloro- 4,4,4-trifluoro-2-butanal (from Step A) was added and the resulting mixture was stined at rt for 20 h. The reaction was quenched with 50 mL of sat'd NH4CI and the resulting mixture was partitioned between 250 mL of ether and 100 mL of water. The organic layer was separated, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (IL), then 4:1 v/v hexanes/CH2Cl2 (IL) as the eluant afforded 5.10 g (78%) of the title compound: IH NMR (400 Mhz) δ 1.40 (t, J= 7.2, 3H), 4.39 (q, J= 7.2, 2H), 7.42 (app s, 5H), 7.74 (q, J=1.6, IH).
Step C: (4-Phenyl-5-trifluoromethyl)thiophene-2-carboxylic acid
A solution of 5.10 g (17.0 mmol) of ethyl 4-phenyl-5-trifluoromethyl- thiophene-2-carboxylate (from Step B) in 20 mL of EtOH was treated with 10 mL of 5.0 N NaOH and stined at rt for 30 min. The EtOH was removed in vacuo. The residual aqueous mixture was acidified to pH 2 with 1 N HCl, then extracted with 300 mL of 1:1 v/v EtO Ac/ether. The extract was separated, dried and concentrated. Recrystallization from 200 mL of 20: 1 v/v hexanes/ether afforded 4.30 g (93%) of the title compound: iH NMR (500 Mhz) δ 7.43 (app s, 5H), 7.84 (app s, IH); 13c NMR (CDCI3, 125 Mhz) δ 121.7 (q, J= 269), 128.5, 128.6, 128.8, 132.5 (q, J= 36),
133.3, 133.8, 137.5, 144.8, 167.0.
Step D: 3-[4-(Carbomethoxy)phenyl]-5-(4-phenyl-5-trifluoromethyl-2-thienyl)- 2,4-oxadiazole A solution of 408 mg (1.5 mmol) of 4-phenyl-5-trifluoromethyl- thiophene-2-carboxylic acid and 1 mL of oxalyl chloride in 5 mL of CH2CI2 was treated with 5 drops of DMF. The resulting mixture was stined at rt for 1 h, then concentrated. The crude acid chloride and 291 mg (1.5 mmol) of 4- (carbomethoxy)benzamidoxime were dissolved in 7 mL of 6:1 v/v xylenes/pyridine. The resulting solution was heated at 140 °C for 1 h, then cooled. The mixture was partitioned between 50 mL of 1:1 EtO Ac/ether and 50 mL of 1 N HCl. The organic layer was separated, washed with 3 x 50 mL of 1 N HCl, 50 mL of sat'd NaHCO3, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (IL), then 20:1 v/v hexanes/EtOAc (IL) as the eluant afforded 423 mg (65%) of the title compound: lH NMR (500 Mhz) δ 3.97 (s, 3H), 7.48 (app s, 5H), 7.92 (s, IH), 8.18 (app d, J= 8.5, 2H), 8.23 (app d, J= 8.5, 2H).
Step E: 3-[4-(Hydroxymethyl)phenyl]-5-(4-phenyl-5-trifluoromethyl-2- thienyl)-l,2,4-oxadiazole
A solution of 390 mg (0.91 mmol) of 3-[4-(carbomethoxy)phenyl]-5- (4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4-oxadiazole (from Step D) in 10 mL of CH2CI2 at -78 oc was treated with 2.7 mL of 1.0 M DIBALH solution in CH2CI2. The resulting solution was stined cold for 1 h, then quenched with 5 mL of sat'd
Rochelle salt solution. The mixture was partitioned between 100 mL CH2CI2 and 50 mL of 1 N NaOH. The organic layer was separated, dried and concentrated. Chromatography on a Biotage 40 S cartridge using 4:1 v/v hexanes/EtOAc (IL) as the eluant afforded 325 mg (89%) of the title compound: lH NMR (500 Mhz) δ 1.80 (app s, IH), 4.80 (d, J= 4.0, 2H), 7.46-7.48 (5H), 7.52 (d, J= 8.0, 2H), 7.91 (q, J= 1.5, IH), 8.14 (d, J= 8.0, 2H).
Step F: 3- [4-(Formyl)phenyl] -5-(4-phenyl-5-trifluoromethyl-2-thienyl)- 1 ,2,4- oxadiazole A mixture of 310 mg (0.77 mmol) of 3-[4-(hydroxymethyl)phenyl]-5-
(4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4-oxadiazole (from Step E), 527 mg (1.5 mmol) of 4-methyJmorpholine N-oxide and 500 mg of 4 A molecular sieves in 15 mL of CH3CN was treated with 12 mg (0.034 mmol) of tetrapropylammonium penuthnate and the resulting mixture was stirred ar rt for 2 h. The solids were filtered and the filtrated was concentrated. Chromatography on a Biotage 40 S cartridge using 9:1 v/v hexanes/EtOAc (IL) as the eluant afforded 205 mg (66%) of the title compound: lH NMR (500 Mhz) δ 7.48 (app s, 5H), 7.93 (app s, IH), 8.03 (d, J= 8.5, 2H), 8.33 (d, J= 8.5, 2H), 10.1 (s, IH).
Aldehyde XVI
4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzaldehyde Step A: 2-Hydroxymethyl-4-phenyl-5-trifluoromethyl-thiophene
A solution of 2.10 g (7.7 mmol) of 4-phenyl-5-trifluoiOmethyl- thiophene-2-carboxylic acid (from Aldehyde XV, Step C) in 20 mL of THF was treated with 5.0 mL of 2.0 M borane dimethylsulfide complex in THF. The resulting solution was heated at reflux for 3 h, cooled to rt, quenched with 10 mL of MeOH and concentrated. Chromatography on a Biotage 40M cartridge using 9:1 v/v hexanes/EtOAc as the eluant afforded 1.95 g (98%) of the title compound: lH NMR (500 Mhz) δ 2.05 (app s, IH), 4.87 (s, 2H), 6.99 (s, IH), 7.41 (app s, 5H).
Step B: 4-((4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehvde
A solution of 1.95 g (7.5 mmol) of 2-hydroxymethyl-4-phenyl-5- trifluoromethyl-thiophene (from Step A), 925 mg (7.6 mmol) of 4- hydroxybenzaldehyde and 3.0 g (11.4 mmol) of triphenylphosphene in 40 mL of THF at 0 oc was treated with 2.0 g (11.4 mmol) of diethylazodicarboxylate. The resulting mixture was warmed to rt, stined for 2 h, then concentrated. Chromatography on a Biotage 75S cartridge using 9:1 v/v heptane/EtOAc as the eluant afforded 2.5 g of impure title compound. Chromatography on a Biotage 40M cartridge using 19:1 v/v hexanes/EtOAc (IL), then 4:1 v/v hexanes/EtOAc (IL) as the eluant afforded 1.65 g (60%) of the title compound: lH NMR (500 Mhz) δ 5.32 (s, 2H), 7.10 (d, J= 8.5, 2H), 7.12 (s, IH), 7.41-7.43 (5H), 7.85-7.90 (2H), 9.92 (s, IH).
Aldehydes 17-21 were prepared using procedures analogous to those described in Aldehyde 16 substituting the appropriately substituted benzaldehyde for 4- (hydroxy)benzaldehyde in Step B:
Aldehyde XVH 3-((4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehyde
Aldehyde XVHI 2-Chloro-4-((4-phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehyde
Aldehyde XIX 3-Chloro-4-((4-phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehyde Aldehyde XX 3-Methyl-4-((4-phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehyde
Aldehyde XXI
3-Methoxy-4-((4-phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehyde
Aldehyde XXH 4-(4-Phenylbutoxy)benzaldehyde The title compound was prepared using a procedure analogous to
Aldehyde TV substituting 4-(iodobutyl)benzene for 1-iodooctane: ESI-MS 255.2 (M+H)
Aldehyde XXTfl 4-(Non- 1 -oyl)benzaldehyde
Step A: 4-(l-Hvdroxynon-l-yl)benzaldehyde
Terephthaldicarboxaldehyde (2.00 g, 14.91 mmol) was dissolved in tetrahydrofuran (25 ml) and cooled to 0°C. Octylmagnesium chloride (7.5 ml, 2.0M in THF, 15 mmol) was added dropwise. After 15 minutes, the reaction was quenched with 2N aqueous hydrochloric acid (50 ml) and diluted with ethyl acetate (50 ml). The organic layer was separated, washed with sat'd NaCl (50 ml), dried over magnesium sulfate and concentrated . Silica gel chromatography eluting with 91:9 v/v hexane/EtOAc gave 0.19 g (0.77 mmol, 5.1%) of the title compound: Η NMR (500 MHz) δ 10.0 (s, IH), 7.87 (d, J = 8.0, 2H), 7.52 (d, J = 8.3, 2H), 4.75-4.80 (m, IH), 1.68-1.82 (m, 2H), 1.22-1.45 (m, 12H), 0.91 (t, J = 7.0, 3H).
Step B: 4-(Non-l-oyl)benzaldehyde
Dess-Martin periodinane (0.268 g, 0.632 mmol) was added to a solution of 4-(l-hydroxynon-l-yl)benzaldehyde (0.125 g, 0.505 mmol) from Step A in CH2CI2 (3.0 ml). After 1 h, the reaction was filtered and concentrated. Silica gel chromatography eluting with 19:1 v/v hexane/EtOAc gave 0.107 g (0.446 mmol, 88%) of the title compound: Η NMR (500 MHz) δ 10.1 (s, IH), 8.10 (d, J = 8.2, 2H), 7.97 (d, J = 8.2, 2H), 3.00 (t, J = 7.3, 2H), 1.70-1.8 (m, 2H), 1.22-1.42 (m, 10H), 0.88 (t, J = 7.0, 3H).
Aldehyde XXIV Heptyl 4-(formyl)benzoate
The title compound was prepared through a condensation between 1- heptanol and 4-formylbenzoic acid. Η NMR (500 MHz , CDCI3): δ 10.10 (s, IH),
8.20 (d, J = 8.2, 2H), 7.95 (d, J = 8.2, 2H), 4.35 (t, J = 6.8, 2H), 1.75-1.85 (m, 2H), 1.40-1.50 (m, 2H), 1.25-1.40 (m, 6H), 0.89 (t, J = 7.0, 3H).
Aldehydes XXV and XXVI were prepared using procedures analogous to those described in Aldehyde 16 substituting the appropriately substituted alcohol for 2- hydroxymethyl-4-phenyl-5-trifluoromethyl-thiophene in Step B:
Aldehyde XXV
4-[(Benzothien-2-yl)methoxy]benzaldehyde
Η NMR (500 MHz) δ 5.34 (s, 2H), 7.04 (d, J = 8.7, 2H), 7.18 (s, IH), 7.25-7.30 (m, 4H), 7.76 (d, J = 8.7, 2H), 9.82 (s, IH).
Aldehyde XXVI
4-[(2,3-Diphenyl-2H-pyrazol-5-yl)methoxy]benzaldehyde
Η NMR (500 MHz) δ 5.21 (s, 2H), 6.55 (s, IH), 7.10 (d, J = 8.7, 2H), 7.14-7.17 (m, 5H), 7.21-7.30 (m, 5H), 7.79 (d, J = 8.7, 2H), 9.82 (s, lH).
PREPARATION OF EXAMPLES
EXAMPLE I
(R/S)-l-(4-(Nonyl)phenyl)methyl-3-hydroxy-pynolidin-3-yl)phosphonic acid
Step A: (R/S)-l-tert-Butoxycarbonyl-3-hydroxypynolidine A solution of 2.5 g (28.7 mmol) of (R/S)-3-hydroxypynolidine in 10 mL of CH2CI2 at 0 °C was treated with 6.89 g (31.6 mmol) of di-tert-butyl- dicarbonate in 2 mL CH2CI2 and 0.35 g (2.8 mmol) of 4-(N,N-dimethylamino) pyridine. After stirring for 10 min, the reaction was warmed to rt and stined overnight. The reaction was diluted with 100 mL of CH2CI2 and washed with 100 mL of IN HCl and 100 mL of IN NaHCθ3. The organic layer was dried over Na2SO4 and concentrated. The residue was purified on a 40M Biotage column using 7:3 v/v hexane/acetone as the eluant to afford 5.3 g (99%) of the title compound: Rp: 0.26 (7:3 v/v hexane/acetone); iH-NMR (500 MHz) δ 1.45 (s, 9H), 1.88-2.00 (m, 2H), 2.52 (br s, IH), 3.29-3.50 (m, 4H), 4.42 (m, IH).
Step B: l-tert-Butoxycarbonyl-3-oxo-pynolidine
A solution of 2.3 mL (26 mmol) of oxalyl chloride in 80 mL of CH2C12 at -78 °C was treated with 3.8 mL (53 mmol) of DMSO in 5 mL of CH2C12. The resulting mixture was stined cold for 5 min. A solution of 2.0 g (10.7 mmol) of
(R/S)-l-tert-butoxycarbonyl-3-hydroxypyrrolidine (from Step A) in 10 mL of CH2C1 was added. The resulting mixture was stined for 30 min, treated with 18.7 mL (107 mmol) of D1EA and warmed to 0 °C. After stirring for 45 min, the reaction was quenched with H2O and poured into 100 mL of IN HCl. After separating the layers, the organic layer was washed with 100 mL sat'd NaCl, dried over Na2SO4 and concentrated. The residue was purified on a 40M Biotage column using 4:1 v/v hexane/acetone as the eluant to afford 1.9 g (96%) of the title compound: Rp: 0.49
(7:3 v/v hexane/acetone); iH-NMR (500 MHz) δ 1.48 (s, 9H), 2.58 (t, J = 7.9, 2H),
3.71-3.78 (m, 4H).
Step C: (R/S)-l-tert-Butoxycarbonyl-3-hydroxy-pyrrolidin-3-yl phosphonic acid, diethyl ester
A mixture of 1.9 g (10.3 mmol) of l-tert-butoxycarbonyl-3- oxopynolidine (from Step B), 1.3 mL (10.3 mmol) of diethyl phosphite and 1.4 mL (10.3 mmol) of TEA was stined at 100 °C for 1.5 h. Volatiles were removed under reduced pressure. The residue was purified on a 40M Biotage column using 13:7 v/v hexane/acetone as the eluant to afford 1.78 g (53%) of the title compound as a yellow oil: RF: 0.16 (7:3 v/v hexane/acetone); iH-NMR (500 MHz) δ 1.33 (t, J = 7.0, 6H), 1.45 (s, 9H), 2.08 (m, IH), 2.18 (m, IH), 3.47-3.64 (m, 4H), 4.13-4.22 (m, 4H).
Step D: (R S)-3-Hydroxy-pynolidin-3-yl phosphonic acid, diethyl ester A solution of 1.78 g (5.5 mmol) of (R/S)-l-tert-butoxycarbonyl-3- hydroxy-pyrrolidin-3-yl phosphonic acid, diethyl ester (from Step C) in 2N HCl in EtOH was stined at rt for 5.5 h. The reaction was concentrated from CH2CI2 several times. The crude product was partitioned between aqueous NH4OH and CHCl3/isopropanol (3:1 v/v). After separating phases, the aqueous layer was extracted with 3X CHCl3/isopropanol (3:1 v/v). The combined organics were dried over Na2SO4 and concentrated. The residue was purified on a 40S Biotage column using 90:10:1 v/v/v CH2Cl2/MeOH NH4θH as the eluant to afford the title compound as a light brown oil: iH-NMR (500 MHz) δ 1.35 (t, J = 7.0, 6H), 1.92 (m, IH), 2.20 (m, IH), 2.78-2.99 (m, 3H), 3.06 (dd, J = 12.7, 3.7, IH), 3.13 (dd, J = 12.7, 6.2, IH), 3.20 (m, IH), 4.16-4.23 (m, 4H).
Step E: (R/S)-l-(4-(Nonylphenyl)methyl-3-hydroxy-pynolidin-3-yl phosphonic acid, diethyl ester
A solution of 60 mg (0.23 mmol) of (R S)-3-hydroxypynolidin-3- ylphosphonic acid, diethyl ester (from Step D) and 54 mg (0.23 mmol) of Aldehyde I in 1.5 mL of CH2CI2 was treated with 73 mg (0.34 mmol) of sodium triacetoxyborohydride. After 3 h at rt, the reaction was diluted with 25 mL of CH2CI2 and washed with 25 mL of IN NaHCO3. After separating phases, the aqueous layer was extracted with 25 mL of CH2C12- The combined organic layers were washed with 50 mL of sat'd NaCl, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography using 3:1 v/v hexane/acetone as the eluant to afford 33 mg (32%) of the title compound: RF: 0.31 (7:3 v/v hexane/acetone); iH-NMR
(500 MHz) δ 0.89 (t, J = 7.0, 3H), 1.27-1.36 (m, 18H), 1.57-1.63 (m, 2H), 1.97 (m,
IH), 2.41-2.54 (m, 2H), 2.59 (t, J = 7.7, 2H), 2.85-2.92 (m, 2H), 3.01 (m, IH), 3.67 (ABq, J = 13.1, 2H), 4.16-4.23 (m, 4H), 7.12 (d, J = 7.8, 2H), 7.24 (d, J = 7.8, 2H).
Step F: (R/S)-l-(4-Nonylbenzyl)-3-hvdroxypyrrolidin-3-ylphosphonic acid A solution of 33 mg (0.075 mmol) of (R/S)-l-(4-nonylbenzyl)-3- hydroxypyιiOlidin-3-ylphosphonic acid, diethyl ester (from Step E) in 1 mL of chloroform was treated with 0.053 mL (0.37 mmol) of iodotrimethylsilane. The reaction was allowed to stir at rt for lh. The reaction was quenched with MeOH and concentrated several times from MeOH. The residue was purified using LC-2 to afford 4.6 mg (16%) of the title compound: ESI-MS 385 (M+H); LC-1: 3.01 min.
EXAMPLES H-X
EXAMPLES H-X were prepared using procedures analogous to those described in EXAMPLE I substituting the appropriate Aldehyde in Step E. TMS-Br was substituted in Step F with substrates containing TMS-I sensitive functionality (See EXAMPLE 11, Step D). In EXAMPLES V and VI enantiomers were resolved after Step E by preparative chiral HPLC (Chiralpak AD 2 x 25 cm HPLC column, 9: 1 v/v hexane/EtOH, flow rate = 9.0 mL/min, λ = 210 nM).
Figure imgf000058_0001
Figure imgf000058_0002
Figure imgf000059_0001
EXAMPLE XI
(R/S)-l-(4-Nonylphenyl)methyl-pyrrolidin-3-yl phosphonic acid
Step A: (R/S)-l-Benzyl-pynolidin-3-yl phosphonic acid, diethyl ester
A solution of 6.0 g (36.6 mmol) of diethyl vinylphosphonate and 11 mL (44 mmol) of N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine in 150 mL of CH2CI2 at 0 °C was stined for 30 min. The reaction mixture was washed with 150 mL of IN NaHCO3 and 150 mL of sat'd NaCl. The organic layer was dried over Na2SO4 and concentrated. The residue was purified on a 40L Biotage column using 3:2 and 1 : 1 v/v hexane/acetone as the gradient to afford 9.44 g (87%) of the title compound as a pale yellow oil: RF: 0.24 (3:2 v/v hexane/acetone); H-NMR (500 MHz) δ 1.32 (t, J = 7.0, 6H), 2.04-2.12 (m, 2H), 2.39-2.58 (m, 3H), 2.83 (m, IH), 2.97 (m, IH), 3.64 (s, 2H), 4.06-4.16 (m, 4H), 7.24-7.34 (m, 5H); ESI-MS 298 (M+H); LC-1: 1.2 min.
Step B: (R/S)-Pynolidin-3-ylphosphonic acid, diethyl ester
A mixture of 3 g (10 mmol) of (R S)-l-benzyl-pynolidin-3- ylphosphonic acid, diethyl ester (from Step A), 9.5 g (150 mmol) of ammonium formate and 1.0 g of 10% palladium on charcoal in 60 mL of MeOH was warmed to 40 oc for 1.5 h. The reaction was cooled, filtered through a pad of celite and concentrated. The mixture was partitioned between 75 mL of IN NaOH and 100 mL of CH2CI2. After separating layers, the aqueous phase was extracted with 3X100 mL of CH2C12- The combined organic layers were dried over Na2SO4 and concentrated.
The residue was purified on a 40M Biotage column using 90:10:1 v/v/v CH2Cl2/MeOH/NH4θH as the eluant to afford the title compound as a pale yellow oil: RF: 0.13 (95:5:0.5 v/v/v CH2Cl2/MeOH/NH4θH); iH-NMR (500 MHz) δ 1.22 (t, J = 7.1, 6H), 1.81 (m, IH), 1.95 (m, IH), 2.25 (m, IH), 2.73 (m, IH), 2.89-2.99 (m, 3H), 4.06-4.16 (m, 4H).
Step C: (R/S)- 1 -(4-Nonylphenyl)methyl-pynolidin-3-ylphosphonic acid, diethyl ester
A solution of 41 mg (0.19 mmol) of (R/S)-pynolidin-3-yl phosphonic acid, diethyl ester (from Step B) and 43 mg (0.18 mmol) of Aldehyde I in 1 mL of CH2CI2 was treated with 57 mg (0.27 mmol) of sodium triacetoxyborohydride. After stirring at rt overnight, the reaction was diluted with 25 mL of CH2CI2 and washed with 25 mL of IN NaHCO3. After separating phases, the aqueous layer was extracted with 25 mL of CH2CI2. The combined organic layers were washed with 50 mL of sat'd NaCl, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography using 49:1 v/v CH2θ2/MeOH as the eluant to afford 67 mg (99%) of the title compound: Rp: 0.39 (19:1 v/v CH2Cl2/MeOH); iH-NMR (500 MHz) δ 0.90 (t, J = 7.0, 3H), 1.20-1.35 (m, 17H), 1.59-1.65 (m, 2H), 2.04-2.13 (m, 3H), 2.41- 2.62 (m, 5H), 2.85 (m, IH), 2.99 (m, IH), 3.62 (s, 2H), 4.08-4.17 (m, 4H), 7.14 (d, J = 8.0, 2H), 7.24 (d, J = 8.0, 2H).
Step D: (R/S)- 1 -(4-Nonylbenzyl)-pynOlidin-3-ylphosphonic acid
A solution of 67 mg (0.16 mmol) of (R/S)-l-(4-nonylbenzyl)- pynolidin-3-ylphosphonic acid, diethyl ester (from Step C) in 1 mL of acetonitrile was treated with 0.094 mL (0.71 mmol) of bromotrimethylsilane. The reaction was allowed to stir at 80 °C for lh. The reaction was quenched with MeOH and concentrated several times from MeOH. The residue was purified by LC-2 to afford 27 mg (46%) of the title compound: ESI-MS 368 (M+H); LC-1: 3.1 min.
EXAMPLES xπ-xvπ
EXAMPLES XH-XVH were prepared using procedures analogous to those described in EXAMPLE XI substituting the appropriate Aldehyde in Step C. In EXAMPLES XV and XVI enantiomers were were resolved after Step E by preparative chiral HPLC (Chiralcel OD 2 x 25 cm HPLC column, 19:1 v/v hexane/iPrOH, flow rate = 9.0 mL/min, λ = 210 nM).
Figure imgf000061_0001
Figure imgf000061_0002
Figure imgf000062_0001
EXAMPLE XVIH
(R S)-l-{4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzyl}-pynolidin-3-yl carboxylic acid
Step A: (R S)-l-Benzyl-pyrrolidin-3-yl carboxylic acid, benzyl ester
A solution of 10.0 g (61.6 mmol) of benzyl acrylate and 19 mL (74.2 mmol) of N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine in 75 mL of CH2CI2 at 0 oc was treated with 0.5 mL (6.5 mmol) of TFA while maintaining the internal temperature at less than 3 oc. The reaction was warmed to rt and stined for 2.5 h. The reaction mixture was washed with 250 mL of IN NaHCO3 and 250 mL of sat'd NaCl. The organic layer was dried over Na2SO4 and concentrated. The residue was purified on a 40L Biotage column using 19:1 v/v hexane/acetone as the eluant to afford 18 g (99%) of the title compound as a light yellow oil: RF: 0.28 (9:1 v/v hexane/acetone); iH-NMR (500 MHz) δ 2.15-2.20 (m, 2H), 2.60 (m, IH), 2.73-2.77 (m, 2H), 3.02 (m, IH), 3.13 (m, IH), 3.66-3.73 (m, 2H), 5.17 (s, 2H), 7.28-7.42 (m, 5H).
Step B: (R S)-l-Benzyloxycarbonyl-pynolidin-3-yl carboxylic acid, benzyl ester
A solution of 18 g (61 mmol) of (R/S)-l-benzyl-pynolidin-3-yl carboxylic acid, benzyl ester (from Step A) in 100 mL of CH2CI2 at 0 °C was treated with 21.3 mL (231 mmol) of benzyl chloroformate while maintaining the internal temperature at less than 6 oc. The reaction was allowed to warm to rt overnight. After 24 hours at rt, an additional 10 mL (10.8 mmol) of benzyl chloroformate was added. After 24 hours of stining at rt, the reaction was concentrated. The residue was purified on a 40L Biotage column using 19:1 v/v hexane/acetone as the eluant to afford 8.42 g (39%) of the title compound as a colorless oil: RF: 0.14 (9:1 v/v hexane/acetone); iH-NMR (500 MHz) δ 2.19-2.22 (m, 2H), 3.15 (m,lH), 3.45-3.75 (m, 4H), 5.13-5.20 (m, 4H), 7.33-7.41 (m, 10H).
Step C: (R S)-Pynolidin-3-yl carboxylic acid
A mixture of 8.4 g (24.7 mmol) of (R/S)-l-benzyloxycarbonyl- pynolidin-3-yl carboxylic acid, benzyl ester (from Step B) and 2.86 g of 10% palladium on charcoal in 80 mL of MeOH was hydrogenated at atmospheric pressure using a balloon of hydrogen for 6.5 h. The reaction was filtered through a pad of
Celite and concentrated to afford 2.72 g (95%) of the title compound as a white solid: iH-NMR (500 MHz, CD3OD) δ 2.17-2.26 (m, 2H), 3.03 (m, IH), 3.24-3.38 (m, 3H),
3.51 (m, IH).
Step D: (R/S)-l-{4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzyl}- pynolidin-3-yl carboxylic acid A mixture of 17.5 mg (0.15 mmol) of (R/S)-pynolidin-3-yl carboxylic acid (from Step C), 78 mg (0.21 mmol) of Aldehyde XVI and 9 mg (0.14 mmol) of sodium cyanoborohydride in 2 mL of MeOH was stined at rt overnight. The reaction was concentrated and purified by flash chromatography using 19:1 v/v CH2Cl2/MeOH, then 85:15:1.5 v/v/v CH2Cl2/MeOH/NH4OH as the eluant to afford 42 mg (63%) of the title compound as a white foam: RF: 0.29 (85: 15: 1.5 v/v/v CH2Cl2/MeOH NH4OH); iH-NMR (500 MHz, CD3OD) δ 2.23-2.35 (m, 2H), 3.09 (m, IH), 3.26-3.41 (m, 3H), 3.53 (m, IH), 4.30 (ABq, J = 13.0, 2H), 5.38 (s, 2H), 7.13 (d, J = 8.5, 2H), 7.22 (s, IH), 7.39-7.45 (m, 5H), 7.48 (d, J = 8.5, 2H); ESI-MS 462 (M+H); LC-1: 2.7 min.
EXAMPLES XTX-XXXm EXAMPLES 19-33 were prepared using procedures analogous to those described in EXAMPLE 18 substituting the appropriate Aldehyde in Step D.
Figure imgf000064_0001
Figure imgf000064_0002
Figure imgf000065_0001
Figure imgf000066_0001
EXAMPLE XXXV
(R/S)-l-(4-Nonylphenyl)methyl-3-fluoro-pynolidin-3-yl carboxylic acid
Step A: (R/S)-l-Benzyl-pynolidin-3-yl carboxylic acid, methyl ester
The title compound was prepared using a procedure analogous to that described in EXAMPLE XVHI, Step A substituting methyl acrylate for benzyl acrylate: RF: 0.29 (9:1 v/v hexane/acetone); lH-NMR (500 MHz) δ 2.10-2.14 (m,
2H), 2.55 (m, IH), 2.66 (m, IH), 2.75 (m, IH), 2.94 (m, IH), 3.06 (m, IH), 3.65 (s, 2H), 3.69 (s, 3H), 7.25-7.35 (m, 5H).
Step B: (R/S)-Pynolidin-3-yl carboxylic acid, methyl ester hydrochloride salt
A solution of 0.52 g (2.3 mmol) of (R/S)-l-benzyl-pyrrolidm-3-yl carboxylic acid, methyl ester (from Step A) in 5 mL of 1,2-dichloroethane was treated with 0.3 mL (2.7 mmol) of 1-chloroethyl chloroformate (ACE-C1). The resulting mixture was stined at rt for 3 h, then at reflux for 30 min. The reaction was cooled and concentrated. The residue was warmed to reflux in 5 mL of MeOH for 1 h. The reaction was cooled and concentrated. The crude product was used in Step C without further purification.
Step C: (R/S - l-(4-Nonylphenyl)methyl-pynolidin-3-yl carboxylic acid, methyl ester
The title compound was prepared using an analogous procedure described in EXAMPLE I, Step E substituting (R/S)-pynolidin-3-yl carboxylic acid, methyl ester hydrochloride salt (from Step B) for (R S)-3-hydroxypynolidin-3- ylphosphonic acid, diethyl ester and using DIEA to neutralize the hydrochloride salt: RF: 0.44 (4:1 v/v hexane/acetone); iH-NMR (500 MHz) δ 0.91 (t, J = 6.9, 3H), 1.30-
1.35 (m, 12H), 1.60-1.66 (m, 2H), 2.13-2.17 (m, 2H), 2.54-2.69 (m, 4H), 2.80 (m, IH), 2.99 (m, IH), 3.09 (m, IH), 3.66 (s, 2H), 3.72 (s, 3H), 7.16 (d, J = 8.0, 2H), 7.27 (d, J = 8.0, 2H).
Step D: (R/S)-l-(4-Nonylphenyl)methyl- 3-fluoropynolidin-3-yl carboxylic acid, methyl ester
To a solution of 1 mL (0.32 mmol) of 0.32M lithium diisopropylamide in THF at -78 oc was added 90 mg (0.26 mmol) of (R S)-l-l-(4-nonylphenyl) methylbenzyl)-pynolidin-3-yl carboxylic acid, methyl ester (from Step C) in 1.5 mL of THF while maintaining the internal temperature at less -70 °C. After 15 min, 111 mg (0.35 mmol) of fluorobenzenesulfonimide in 0.5 mL THF was added while maintaining the internal temperature at less -68 °C. After stirring for 15 min, the reaction was warmed to 0 oc and quenched with 0.1N HCl. The reaction mixture was poured into 50 mL of Et2θ and washed with 50 mL of IN NaHCO3 and 50 mL of sat'd NaCl. The organic phase was dried over MgSO4 and concentrated. The residue was purified by flash chromatography using 19:1 v/v hexane/acetone as the eluant to afford 47 mg (50%) of the title compound as a colorless film: RF: 0.36 (9: 1 v/v hexane/acetone); iH-NMR (500 MHz) δ 0.91 (t, J = 6.8, 3H), 1.30-1.35 (m, 12H), 1.60-1.66 (m, 2H), 2.28 (m, IH), 2.49 (m, IH), 2.62 (t, J = 7.8, 2H), 2.69 (m, IH), 2.95-3.10 (m, 3H), 3.69 (ABq, J = 12.8, 2H), 3.83 (s, 3H), 7.16 (d, J = 7.8, 2H), 7.27 (d, J = 7.8, 2H). Step E: (R/S)-l-(4-Nonylphenyl)methyl-3-fluoropyιτolidin-3-yl carboxylic acid
A solution of 46 mg (0.12 mmol) of (R/S)-l-(4-nonylphenyl)methyl-3- fluoropynolidin-3-yl carboxylic acid, methyl ester (from Step D) in 3 mL of EtOH was treated with 0.16 mL (0.16 mmol) of IN NaOH and stined overnight at rt. The reaction was neutralized with 2 mL of pH 7 buffer and concentrated. Toluene was added and the resulting mixture was concentrated. The residue was purified by flash chromatography using 19:1 v/v CH2Cl2/MeOH, then 90:10:1 v/v/v CH2Cl2/MeOH/NH4OH as the eluant to afford 38 mg (86%) of the title compound as a white, waxy solid: Rp: 0.21 (85:15:1.5 v/v/v CH2Cl2/MeOH/NH4OH); iH-NMR (500 MHz) δ 0.79 (t, J = 6.8, 3H), 1.18-1.23 (m, 12H), 1.48-1.52 (m, 2H), 2.30 (m, IH), 2.47-2.59 (m, 3H), 3.29-3.44 (m, 3H), 3.73 (m, IH), 3.87 (br m, IH), 4.17 (ABq, J = 12.9, 2H), 7.12 (d, J = 7.9, 2H), 7.28 (d, J = 7.9, 2H); ESI-MS 350 (M+H); LC-1: 3.3 min.
EXAMPLE XXXVI
(R/S)-l-(4-Nonylphenyl)methyl-3-hydroxypynolidin-3-yl carboxylic acid
Step A: (R/S) l-(4-Nonylphenyl)methyl-3-hydroxypyrrolidin-3-yl carboxylic acid, methyl ester
To a solution of 0.52 mL (0.52 mmol) of 1.0M sodium hexamethylsilazide in THF at -78 oc was added 153 mg (0.44 mmol) of (R S)- 1-(4- nonylphenyl)methyl-pynolidin-3-yl carboxylic acid, methyl ester (from EXAMPLE XXXTV, Step C) in 1 mL of THF while maintaining the internal temperature at less - 72 oc. After 20 min, 172 mg (0.65 mmol) of 2-(phenylsulfonyl)-3-ρhenyloxaziridine (Davis Reagent) in 1 mL of THF was added while maintaining the internal temperature at less -69 oc. After stirring for 1.25 h at -78 oc, the reaction was quenched with IN NaHCO3 and warmed to rt. After removing volatiles under reduced pressure, the reaction mixture was diluted with 50 mL of IN NaHCO3 and 50 mL of sat'd NaCl. The aqueous phase was extracted with 3X50 mL of CH2CI2. The combined organic layers were dried over Na2SO4 and concentrated. The residue was purified by flash chromatography using 4: 1 v/v hexane/EtOAc and 4: 1 v/v hexane/acetone as the gradient to afford 11 mg (7%) of the title compound as a colorless film: RF: 0.39 (4:1 v/v hexane/acetone); iH-NMR (500 MHz) δ 0.90 (t, J =
6.8, 3H), 1.28-1.33 (m, 12H), 1.59-1.64 (m, 2H), 2.02 (m, IH), 2.42 (m, IH), 2.60 (t, J = 7.8, 2H), 2.67 (m, IH), 2.86 (ABq, J = 10.1, 2H), 2.97 (m, IH), 3.69 (s, 2H), 3.82 (s, 3H), 7.14 (d, J = 7.9, 2H), 7.26 (d, J = 7.9, 2H).
Step B: (R/S)- l-(4-Nonylphenyl)methyl-3-hydroxypynolidin-3-yl carboxylic acid
The title compound was prepared using an analogous procedure described in EXAMPLE XXXIV, Step E substituting (R/S)-l-(4-nonylphenyl)methyl- 3-hydroxypynolidin-3-yl carboxylic acid, methyl ester (from Step A) for (R S)-l-(4- nonylphenyl)methyl-3-fluoropyrrolidin-3-yl carboxylic acid, methyl ester: Rp: 0.15 (90:10:1 v/v/v CH2Cl2/ eOH/NH4OH); iH-NMR (500 MHz, CD3OD) δ 0.89 (t, J =
6.9, 3H), 1.28-1.33 (m, 12H), 1.60-1.63 (m, 2H), 2.10 (m, IH), 2.49 (m, IH), 2.64 (t, J = 7.7, 2H), 3.25 (m, IH), 3.49-3.62 (m, 3H), 4.38 (ABq, J = 13.0, 2H), 7.28 (d, J = 7.8, 2H), 7.42 (d, J = 7.8, 2H); ESI-MS 348 (M+H); LC-1: 3.0 min.
EXAMPLE XXXVH
(R/S)-l-(4-Nonylphenyl)methyl-pynolidin-3-yl acetic acid
Step A: (R/S)- l-(4-Nonylphenyl)methyl-pynolidin-3-ylacetic acid, tert-butyl ester
The title compound was prepared using an analogous procedure described in EXAMPLE I, Step E substituting (R/S)-pyrrolidin-3-yl acetic acid, tert- butyl ester hydrochloride salt for (R/S)-3-hydroxypynolidin-3-ylphosphonic acid, diethyl ester and using DIEA to neutralize the hydrochloride salt: Rp: 0.53 (4:1 v/v hexane/acetone); iH-NMR (500 MHz) δ 0.90 (t, J = 6.8, 3H), 1.28-1.64 (m, 25H), 2.09 (m, IH), 2.26-2.37 (m, 3H), 2.58-2.69 (m, 4H), 2.89 (m, IH), 3.61-3.64 (m, 2H), 7.14 (d, J = 7.4, 2H), 7.26 (d, J = 7.4, 2H).
Step B: (R S)-l-(4-Nonylphenyl)methyl-pynolidin-3-yl acetic acid A solution of 50.5 mg (0.12 mmol) of (R/S)-l-(4-nonylphenyl)methyl- pyιτolidin-3-yl acetic acid, tert-butyl ester (from Step A) in formic acid at 55 oc was stined for 2.25 h. Volatiles were removed under reduced pressure. The residue was purified by flash chromatography using 19:1 v/v CH2θ2/MeOH, then 85:15:1.5 v/v/v CH2Cl2/MeOH/NH4OH as the eluant to afford 41 mg (94%) of the title compound as a sticky, waxy film: RF: 0.31 (85:15:1.5 v/v/v CH2Cl2/MeOH NH4OH); iH-NMR (500 MHz, CD3OD) δ 0.90 (t, J = 6.9, 3H), 1.29-1.33 (m, 12H), 1.61-1.64 (m, 2H), 1.77 (m, IH), 2.26-2.45 (m, 3H), 2.64 (t, J = 7.7, 2H), 2.71 (m, IH), 3.08 (m, IH), 3.23 (m, IH), 3.38-3.44 (m, 2H), 4.28 (s, 2H), 7.28 (d, J = 8.1, 2H), 7.39 (d, J = 8.1, 2H); ESI-MS 346 (M+H); LC-1: 3.3 min.
EXAMPLE XXXVIJJ
(R S)- 1 - { 4- [(4-Phenyl-5 -trifluoromethyl-2-thienyl)methoxy]benzyl } -pynolidin-3 - ylacetic acid
The title compound was prepared using procedures analogous to those described in EXAMPLE XXXVI substituting Aldehyde XVI for Aldehyde I in Step
A: RF: 0.29 (85:15:1.5 v/v/v CH2Cl2/MeOH/NH4OH); iH-NMR (500 MHz, CD3OD) δ 1.77 (m, IH), 2.26-2.46 (m, 3H), 2.71 (m, IH), 3.07 (m, IH), 3.23 (m,
IH), 3.37-3.34 (m, 2H), 4.28 (s, 2H), 5.38 (s, 2H), 7.13 (d, J = 8.7, 2H), 7.23 (s, IH),
7.40-7.47 (m, 7H); ESI-MS 476 (M+H); LC-1: 3.0 min.
EXAMPLE XXXIX
(R/S)-5-[l-(4-Nonylphenyl)methylpynolidin-3-yl]-lH-tetrazole
Step A: (R S)-l-Benzyloxycarbonyl-3-cyano pynolidine
The title compound was prepared using analogous procedures described in EXAMPLE XVIΗ (Steps A and B) substituting acrylonitrile for benzyl acrylate in Step A: RF: 0.19 (4:1 v/v hexane/acetone); lΗ-NMR (500 MHz) δ 2.18-
2.28 (m, 2H), 3.12 (m, IH), 3.53 (m, IH), 3.61-3.78 (m, 3H), 5.16 (d, J = 3.0, 2H), 7.32-7.42 (m, 5H). Ste B: (R/S)-5-ri-Benzyloxycarbonyl-pynolidin-3-yll-lH-tetrazole
A mixture of 1.8 g (7.8 mmol) of (R/S)-l-benzyloxycarbonyl-3-cyano pynolidine (from Step A), 1.5 g (23 mmol) of sodium azide and 1.25 g (23 mmol) of ammonium chloride in 70 mL of DMF was stined at 105 oc ovemight. After cooling to rt, the reaction was poured into 150 mL of CΗ2CI2 and washed with 150 mL of IN HCl and 2X150 mL of H2O. The organic phase was dried over MgSO4 and concentrated. The residue was purified on a 40M Biotage column using 80:20:1 v/v/v CH2Cl2/EtOAc/HOAc as the eluant to afford 670 mg (31%) of the title compound: RF: 0.23 (80:20: 1 v/v/v CH2Cl2/EtOAc/HOAc); iH-NMR (500 MHz) δ 2.29, 2.48 (2m, 2H), 3.54-4.03 (m, 5H), 5.14-5.24 (m, 2H), 7.30-7.37 (m, 5H), 10.43 (br, IH).
Step C: (R/S)-5-(Pvnolidin-3-yl)-lH-tetrazole
A mixture of 662 mg (2.4 mmol) of (R/S)-5-[l-benzyloxycarbonyl- pyrrolidin-3-yl]-lH-tetrazole (from Step B) and 220 mg of 10% palladium on charcoal in 5 mL of MeOΗ was hydrogenated at atmospheric pressure using a balloon of hydrogen for 3 h. The reaction was filtered through a pad of Celite and concentrated to afford the title compound as a white solid: lΗ-NMR (500 MHz, CD3OD) δ 2.27
(m, IH), 2.49 (m, IH), 3.39-3.51 (m, 3H), 3.70 (m, IH), 3.85 (m, IH).
Step D: (R S)-5-ri-(4-Nonylbenzyl)methyl-pynolidin-3-vn-lH-tetrazole
The title compound was prepared using an analogous procedure described in EXAMPLE XVIΗ, Step D substituting (R/S)-5-(pynolidin-3-yl)-lH- tetrazole (from Step C) for (R S)-pynolidin-3-yl carboxylic acid: lΗ-NMR (500 MHz, CD3OD) δ 0.89 (t, J = 7.0, 3H), 1.28-1.33 (m, 12H), 160.-1.63 (m, 2H), 2.33
(m, IH), 2.55 (m, IH), 2.64 (t, J = 7.6, 2H), 3.47-3.55 (m, 3H), 3.76 (m, IH), 3.92 (m, IH), 4.40 (s, 2H), 7.29 (d, J = 8.0, 2H), 7.42 (d, J = 8.0, 2H); ESI-MS 356 (M+H); LC-1: 3.3 min.
EXAMPLE XL
l-{4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzyl}-3-azetidinecarboxylic acid The title compound was prepared by treating a mixture of 0.12 mmol of 3-azetidinecarboxylic acid, 0.1 mmol of Aldehyde XVI, 0.007 mL (0.12 mmol) of acetic acid in 2 mL of MeOH with 10 mg (0.16 mmol) of sodium cyanoborohydride and stining the resulting mixture at rt for 3 h. The product was purified using LC-2: lH NMR (500 MHz, CD3OD) δ 3.34-3.37 (m, IH), 4.08 (app s, 2H), 4.10 (app s,
2H), 4.22 (s, 2H), 4.86 (s, 2H), 5.35 (s, 2H), 7.10 (app d, J= 8.0, 2H), 7.20 (s, IH), 7.39-7.43 (5H).
EXAMPLES XLI-XLV
EXAMPLES XLI-XLV were prepared using procedures analogous to that described in EXAMPLE XLI substituting the appropriate Aldehyde for Aldehyde XVI.
Figure imgf000072_0001
Figure imgf000072_0002
Figure imgf000073_0001
EXAMPLES XLVI-LIV
The following compounds were prepared by treating a mixture of 0.12 mmol of either azetidine-3-carboxylic acid or (±)-pynoldine-3-carboxylic acid, 0.1 mmol of Aldehyde, 7 μL (0.12 mmol) of acetic acid in 2 mL of MeOH with 10 mg (0.16 mmol) of sodium cyanoborohydride and stirring the resulting mixture at rt for 1-3 h. The reaction mixtures were purified using LC-2.
Figure imgf000073_0002
Figure imgf000074_0001
XAMPLE LV
(3S,4R or 3R,4S)-l-(4-Nonylbenzyl)-4-trifluoromethylpynolidin-3-yl carboxylic acid
Step A: 4-(Nonyl)benzylamine
4-Nonylbenzoyl chloride (6g, 20mmol) and NH4OAC (6g,) were suspended in acetone (lOOmL) and stined for 1 h at rt. Water (50mL) was added and the mixture filtered. The residue was washed with water and dried . The resulting crude amide (2.47g, -lOmmol) was dissolved in THF (5mL) and borane dimethylsulfide complex (lOmL of 2M solution, 20mmol) was added dropwise, while warming to reflux. The mixture was heated for lh. then cooled in an ice bath. Methanol (2.5mL) was added dropwise, followed by IN HCl in ether (llmL). The white precipitate of the HCl salt of the benzyl amine was filtered off and washed with ether. The HCl salt was taken up in 2.5N NaOH and ether and the organic layer was separated and dried over Na2SO4. Evaporation afforded 1.3 g of the title compound.
Step B: N-(Methoxymethyl)-N-(trimethylsilylmethyl)-(4-nonyl)benzylamine
A solution of 1.3 g (6 mmol) of 4-(nonyl)benzylamine (from Step A) and 700 mg (6 mmol) of chloromethyltrimethylsilane in 5 mL of DMSO was stined at 90 °C for 3 h, then at rt for 16 h. The mixture was partitioned between MTBE and IN NaOH. The organic layer was separated, washed with sat'd NaCl, dried and concentrated. Flash chromatography using 9: 1 v/v hexane/EtOAc as the eluant afforded 700 mg of N-(trimethylsilylmethyl)-4-(nonyl)benzylamine.
A mixture of the crude N-(trimethylsilylmethyl)-4-(nonyl)benzylamine, 140 mg of paraformaldehyde and 15 mg of powdered NaOH in 5 mL of MeOH was stined at 40 oc for 1 h. The mixture was diluted with ether and aged for 16 h. The mixture was concentrated and dried to afford 700 mg of the title compound: lH NMR (500 MHz, CD3OD) δ: 7.25 (m, 2H); 7.15 (m, 2H); 4.03 (m, 2H); 3.74 (m, 2H); 3.28 (m, 2H); 2.61 (m, 2H); 2.22 (m, 2H); 1.63 (m, 4H); 1.30 (m, 14H); 0.90 (m, 3H); 0.08 (m, 9H).
Step C : 1 -(4-(Nonyl)phenyl)methyl-3-(R S)-carboxy-4-(R/S)-trifluoromethyl pynolidine
A solution of 50 mg (0.14 mmol) of N-(methoxymethyl)-N- (trimethylsilylmethyl)-(4-nonyl)benzylamine (from Step B) and 20 mg (0.14 mmol) of trαns-4,4,4-trifluoro-2-butenoic acid (0.137mmol) in 1 mL of CH2CI2 was treated with 1 drop of TFA and the resulting mixture was heated at 35 oc for lh. The reaction was cooled, concentrated then and then purified using LC-2 to afford the title compound: lH NMR (500 MHz, CD3OD) δ 7.25 (d, J = 8, 2H); 7.19 (d, J = 8, 2H); 3.87 (m, 2H); 3.54 (m, IH); 3.27(m, 4H); 2.93 (m, IH); 2.61 (m, 2H); 1.62 (m, 2H); 1.30 (m, 14H); 0.90 (t, J = 6.7, 3H); ESI-MS 400.3 (M+H).
EXAMPLES LVI-LVHI EXAMPLES LVI-LVHI were prepared using procedures analogous to those described in EXAMPLE LV substituting the appropriate ,β-unsaturated acid in Step C.
Figure imgf000076_0001
Figure imgf000076_0002
lH NMR (500 MHz, CD3OD) δ: 7.36 (m, , 4H); 4.43 (m, , IH); 4.14 (m, 3H); 3.79 (m, IH); 3.50 (m, IH); 3.09 (m, 2H); 2.70 (m, 8H); 3.18 (m, IH); 2.65 (m, 2H); 2.3 (m, 2H); 1.61 (m, 2H); 1.29 (M, 14H); 0.89 (m, 3H)
METHODS FOR PREPARING N-(BENZYL)AMINOALKYLCARBOXYLATES. PHOSPHΓNATES AND PHOSPONATES The structures of Examples 1-150 are shown in the following table:
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
GENERAL METHODS Concentration of solutions was carried out on a rotary evaporator under reduced pressure. Conventional flash chromatography was carried out on silica gel (230-400 mesh). Flash chromatography was also canied out using a Biotage Flash Chromatography apparatus (Dyax Corp.) on silica gel (32-63 mM, 60 A pore size) in pre-packed cartridges of the size noted. NMR spectra were obtained in CDCI3 unless otherwise noted. Coupling constants (J) are in hertz (Hz). Abbreviations: diethyl ether (ether), triethylamine (TEA), N,N-diisopropylethylamine (DIEA), tetrahydrofuran (THF), saturated (sat'd), room temperature (rt), hour(s) (h or hr), min(s) (min). For all tables that follow any NMR data follows the compound.
HPLC METHODS LC-1: Waters Xtena MS C18, 5 μ, 4.6 x 50 mm column, 10:90 to 95:5 v/v CH3CN/H2O + 0.05% TFA over 4.5 min, hold 1 min, PDA detection 200-600 nm, flow rate = 2.5 mL/min.
LC-2: Analytical Sales and Service Armor C8 5 μ 20 x 100 mm column, 10:90 to 90:10 v/v CH3CN/H2O + 0.05% TFA over 12 min, hold 4 min, UV detection at either 210, 220 or 254 nM, flow rate = 10 mL/min.
LC-3: YMC-Pack Pro C18, 5μ, 20 mm x 150 mm column, gradient 10:90-80:20 v/v CH3CN:H2O + 0.1% TFA over 23 min then hold at 100:0 v/v CH3CN:H2O + 0.1% TFA for 7 min; 20 mL/min, 254 nm. PREPARATION OF ALDEHYDE INTERMEDIATES
Aldehyde 1 4-Octyloxybenzaldehyde 4-Hydroxybenzaldehyde (1.00 g, 0.82 mmol), potassium carbonate (1.70 g,
12.28 mmol) and 1-iodooctane (2.16 g, 9.00 mmol) were heated together in acetonitrile at 80°C for 16 h. The reaction was cooled, filtered and concentrated. Silica gel chromatography eluting with hexane/ethyl acetate (20:1) gave a colorless oil (1.63 g): Η NMR (500 MHz) δ 9.99 (s, IH), 7.44-7.46 (m, 2H), 7.40 (s, IH), 7.19 (m, IH), 4.01 (t, J=6.6 Hz, 2H), 1.80 (m, 2H), 1.42-1.50 (m, 2H), 1.24-1.39 (m, 8H), 0.89 (t, J=6.9 Hz, 3H).
Aldehyde 2 4-Hydroxy-3-propyloxybenzaldehyde 3,4-Dihydroxybenzaldehyde (0.5 g, 3.62 mmol) was dissolved in DMF
(10 mL) and sodium hydride (0.087 g, 3.62 mmol) was added. The reaction mixture was stined at rt for 10 min. Iodopropane (0.35 mL, 0.62 mmol) was added and the reaction was stined at 80 °C for 2.5 h. The reaction was diluted with ethyl acetate and washed with 2N HCl and water. Silica gel chromatography eluting with 35% ethyl acetate/hexane yielded 0.16 g of desired product: ESI-MS 181 (M+H).
Aldehyde 3 6-Hydroxy-2-naphthaldehyde
Aluminum trichloride (1.07 g, 8.06 mmol) was added to a solution of 6- methoxy-2-naphthaldehyde (1.0 g, 5.37 mmol) in chlorobenzene (15 mL). The reaction mixture was stined at 130 °C for 4 h. The reaction was quenched with water (5 mL) and cone. HCl (2 mL). The reaction mixture was dissolved in ethyl acetate and washed with water and brine and dried over anhydrous magnesium sulfate. Silica gel chromatography eluting with 10% ethyl acetate/hexane yielded 0.35 g of desired product: ESI-MS 173.0 (M+H). Aldehydes 4-34 The following Aldehydes (4-34) were prepared using a procedure analogous to that described for Aldehyde 1 substituting A for 1-iodooctane and B for 4- hydroxybenzaldehyde.
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Aldehyde 35 3-Methoxy-5-methyl-4-octyloxybenzaldehyde
Aldehyde 20 (0.20 g, 0.51 mmol) and tetramethyl tin (0.2 g, 1.12 mmol) were dissolved in N-methyl pynolidinone (1 mL) in a sealed tube. Palladium tetrakis (triphenylphosphine) (0.016 g, 0.014 mmol) and copper iodide (0.01 g, 0.05 mmol) were added to the reaction mixture which was heated at 65° for 16 h. The reaction mixture was diluted with ethyl acetate and washed with 2N HCl, brine and was dried over magnesium sulfate. Silica gel chromatography eluting with 10% ethyl acetate/hexane gave desired product: ESI-MS 279.2 (M+H). Aldehyde 36 3-Methoxy-5-phenyl-4-octyloxybenzaldehyde
Aldehyde 20 (0.25 g, 0.64 mmol), phenylboronic acid (0.12 g, 0.96 mmol), potassium carbonate (0.27 g, 1.92 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.15 g, 0.016 mmol) and 2-(dicyclohexylphosphino)biphenyl (0.022 g, 0.064 mmol) were dissolved in tetrahydrofuran (1 mL). The reaction mixture was stined at rt for 3 h then at 50 °C for 16 h. The reaction mixture was filtered through celite. Silica gel chromatography eluting with 10% ethyl acetate/hexane gave desired product: ESI-MS 341.2 (M+H).
Aldehyde 37 3-Hydroxy-4-octyloxybenz aldehyde
Aldehyde 28 (0.25 g, 0.77 mmol) was dissolved in methylene chloride (4 mL) and boron tribromide dimethylsulfide complex (0.6 g, 1.93 mmol) was added dropwise. The reaction mixture was stined at rt for 1 h. The reaction was quenched with methanol and concentrated in vacuo. Silica gel chromatography eluting with 10% ethyl acetate/hexane yielded 0.155 g of desired product: ESI-MS 251.2 (M+H).
Aldehyde 38
4-(Nonoylamido)benzaldehyde
4-Aminobenzaldehyde (0.3 g, 2.5 mmol) was dissolved in methylene chloride
(8 mL) and nonanoyl chloride (0.5 mL, 2.7 mmol) was added followed by DIEA (1.14 mL, 6.25 mmol). The reaction was stined at rt for 3 h. Silica gel chromatography eluting with 25% ethyl acetate/hexane yielded impure product Further purified by
HPLC to give 30.0 mg of desired product: ESI-MS 262.0 (M+H).
Aldehyde 39 4-(5-Phenylpentyloxy)benzaldehyde Diethylazodicarboxylate (0.49 g, 2.8 mmol) in tetrahydrofuran (2 mL) was added to a solution of 4-hydroxybenzaldehyde (0.25 g, 2.05 mmol), 5-phenyl-l- pentanol (0.34 mL, 2.05 mmol) and triphenylphosphine (0.73 g, 2.80 mmol) in tetrahydrofuran (10 mL) at rt. The reaction was stined for 2h. The reaction mixture was concentrated in vacuo. Silica gel chromatography eluting with 20% ethyl acetate/hexane yielded 0.070 g of desired product: Η NMR (500 MHz , CD3OD): δ 9.83 (s, IH), 7.86 (d, J=8.7 Hz, 2H), 7.25 (t, 2H), 7.14-7.20 (m, 3H), 7.06 (d, J=8.7 Hz, 2H), 4.09 (t, J=6.4 Hz, 2H), 2.65 (t, J=7.7 Hz, 2H), 1.80-1.88 (m, 2H), 1.68-1.75 (m, 2H), 1.49-1.57 (m, 2H).
Aldehyde 40 3 ' -Chloro-4' -octyloxy-4-biphenylbenzaldehyde Step A: 1 -Bromo-3 -chloiO-4-octyloxybenzene l-Bromo-3-chloro-4-hydroxybenzene (0.50 g, 2.41 mmol) was dissolved in acetonitrile (20 mL) and stined at rt. Potassium carbonate (0.47 g, 3.37 mmol) and iodooctane (0.57 mL, 3.13 mmol) were added and the reaction was heated to 80 °C for 4 h. The reaction was diluted with ethyl acetate, washed with water and dried over anhydrous magnesium sulfate. Silica gel chromatography eluting with 1% ethyl acetate/hexane yielded 0.6 g of product: ESI-MS 317.0 (M+H).
Step B: 3'-Chloro-4'-octyloxy-4-biphenylbenzaldehyde Palladium acetate (0.005 g, 0.022 mmol) and 2- (dicyclohexylphosphino)biphenyl (0.015 g, 0.044 mmol) were added to a solution of (4-formylphenyl)boronic acid (0.25 g, 1.65 mmol), 1 -bromo-3 -chloro-4- octoxybenzene (0.35 g, 1.10 mmol, from Step A), and potassium fluoride (0.19 g, 3.30 mmol) in 1,4-dioxane (3 mL). The reaction mixture was heated at 75 °C for 3 h. The reaction was cooled, filtered through celite and concentrated in vacuo. Silica gel chromatography eluting with 1% ethyl acetate/hexane yielded 0.17 g of desired product: Η NMR (500 MHz , CD3OD): δ 10.01 (s, IH), 7.97 (d, J=8.0 Hz, 2H), 7.80 (d, J=8.0 Hz, 2H), 7.74 (s, IH), 7.61 (d, J=7.7 Hz, IH), 7.16 (d, J=8.7 Hz, IH) 4.11 (t, J=6.2 Hz, 2H), 1.80-1.89 (m, 2H), 1.50-1.60 (m, 2H), 1.28-1.46 (m, 8H), 0.88-0.97 (m, 3H)
Aldehydes 41-60
The following Aldehydes (41-60) were made using procedures analogous to those described for Aldehyde 40 substituting A for 1-iodooctane and B for l-bromo-3- chloro-4-hydroxybenzene in Step A
Figure imgf000107_0001
Figure imgf000108_0001
Aldehyde 61 4-(Octyloxymethyl)benzaldehyde Step A: 4-(Octyloxymethyl)benzyl alcohol
Sodium hydride (0.17 g, 7.20 mmol) was added to a solution of 1,4-benzene dimethanol (1.00 g, 7.20 mmol) in THF at 0 °C. The reaction was stined for 1 h. 1- iodooctane (1.73 g; 7.20 mmol) was added and the reaction mixture was warmed to rt for 4 h and then heated at 50°C for 2 days. The reaction was cooled and filtered. Silica gel chromatography eluting with 15% ethyl acetate/hexane gave 0.14 g of product: Η NMR (500 MHz) δ 7.34-7.40 (m, 4H), 4.68-4.72 (m, 2H), 4.51 (s, 2H), 3.46-3.50 (m, 2H), 1.61-1.68 (m, 2H), 1.24-1.40 (m, 10H), 0.88-0.92 (m, 3H). Step B: 4-(Octyloxymethyl)benzaldehyde
4-(Octyloxymethyl)benzyl alcohol (0.14 g, 0.56 mmol, from Step A) was dissolved in methylene chloride (1.5 mL) and the reaction mixture was cooled to 0 °C. 4-methylmorpholine N-oxide (0.10 g, 0.84 mmol) and molecular sieves (4 A) (0.25 g) were added. Tetrapropylammonium penuthenate (0.004 g, 0.011 mmol) was added and the resulting mixture was stined for 1 h. The reaction mixture was filtered through celite. Silica gel chromatography eluting with 6% ethyl acetate/hexane gave 0.018 g of product: Η NMR (500 MHz) δ 10.02 (s, IH), 7.86-7.90 (m, 2H), 7.50- 7.55 (m, 2H), 4.58-4.62 (s, 2H), 3.50-3.55 (m, 2H), 1.62-1.70 (m, 2H), 1.24-1.35 (m, 2H), 0.87-0.93 (m, 2H).
Aldehyde 62 4-(N-Octylcarboxamido)benzaldehyde
DIEA (0.43 mL, 2.33 mmol) was added to a solution of 4- carboxybenzaldehyde (0.23 g, 1.55 mmol), octylamine (0.20 g, 1.55 mmol) and PyBoP (0.89 g, 1.71 mmol) in methylene chloride (2.5 mL). The reaction was stined at rt for 16 h after which it was concentrated. Silica gel chromatography eluting with 25% ethyl acetate/hexane gave 0.30 g of product: ESI-MS 262.1 (M+H).
Aldehydes 63-73 The following Aldehydes (63-73) were made using a procedure analogous to that described for Aldehyde 62 substituting A for octylamine.
Figure imgf000109_0001
Figure imgf000110_0001
Aldehyde 70
4- ( 1 -Hydroxynon- 1 -yl)benzaldehyde
Terephthaldicarboxaldehyde (2.00 g, 14.91 mmol) was dissolved in tetrahydrofuran (25 mL) and cooled to 0°C. Octylmagnesium chloride (7.5 mL, 2.0M in THF, 15 mmol) was added dropwise. After 15 min, the reaction was quenched with 2N aqueous hydrochloric acid (50 mL) and diluted with ethyl acetate (50 mL). The organic layer was separated, washed with sat'd sodium chloride (50 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 9% ethyl acetate/hexane gave 0.19 g (0.77 mmol, 5.1%) of product: Η NMR (500 MHz) δ 10.0 (s, IH), 7.87 (d, J=8.0 Hz, 2H), 7.52 (d, J=8.3 Hz, 2H), 4.75-4.80 (m, IH), 1.68-1.82 (m, 2H), 1.22-1.45 (m, 12H), 0.91 (t, J=7.0 Hz, 3H).
Aldehyde 71 4-(l-Nonoyl)benzaldehyde
Dess-Martin periodinane (0.268 g, 0.632 mmol) was added to a solution of Aldehyde 70 (0.125 g, 0.505 mmol) in methylene chloride (3.0 mL). After 1 h, the reaction was filtered and concentrated in vacuo. Silica gel chromatography eluting with 5% ethyl acetate/hexane gave 0.107 g (0.446 mmol, 88%) of product: Η NMR (500 MHz) δ 10.1 (s, IH), 8.10 (d, J=8.2 Hz, 2H), 7.97 (d, J=8.2 Hz, 2H), 3.00 (t, J= 7.3 Hz, 2H), 1.70-1.8 (m, 2H), 1.22-1.42 (m, 10H), 0.88 (t, J=7.0 Hz, 3H).
Aldehyde 72
4-( 1 -DecanoyPbenzaldehyde
Tetrakis(triphenylphosphine)palladium(0) (50 mg) was added to a solution of 4-formylphenylboronic acid (0.50 g, 3.33 mmol), nonanoyl chloride (1.7 mL, 8.33 mmol) and cesium carbonate (2.70 g, 8.33 mmol) in toluene (40 mL) and heated to 80 °C. After stirring overnight, the reaction was diluted with ethyl acetate (50 mL) and washed with 2N hydrochloric acid (50 mL), sat'd sodium chloride (50 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 6% ethyl acetate/hexane gave 0.022 g (0.083 mmol, 3%) of product: Η NMR (500 MHz) δ 10.1 (s, IH), 8.09 (d, J=8.2 Hz, 2H), 7.98 (d, J=8.2 Hz, 2H), 3.00 (t, J= 7.4 Hz, 2H), 1.70-1.80 (m, 2H), 1.22-1.42 (m, 12H), 0.88 (t, J=6.9 Hz, 3H).
Aldehyde 73
3-Methyl-4-decanoyl benzaldehyde Step A: 4-Bromo-3-methylbenzyl alcohol
DIBALH (1.0M solution in methylene chloride, 31 mL, 31 mmol) was added dropwise to a solution of methyl 4-bromo-3-methylbenzoate (3.0 g, 14.0 mmol) in methylene chloride (20 mL) at 0 °C. After 1 h, the reaction was quenched with 10% aqueous sodium bisulfite (100 mL). The aqueous layer was separated and extracted with methylene chloride (50 mL). The combined organic layers were combined, dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 17% ethyl acetate/hexane gave 1.90 g (9.50 mmol, 68%) of product: Η NMR (500 MHz) δ 7.50 (d, J=8.3 Hz, IH), 7.24 (s, IH), 7.04 (d, J=8.0 Hz, IH), 4.62 (d, J= 5.7 Hz, 2H), 2.40 (s, 3H).
Step B: 4-( 1 -Hydroxydec- 1 -yl)-3-methylbenzyl alcohol n-Butyllithium (2.5 M in hexanes, 8.3 mL, 20.7 mmol) was added dropwise to a solution of 4-bromo-3-methylbenzyl alcohol (1.90 g, 9.44 mmol, from Step A) in tetrahydrofuran (25 mL) at -78 °C. After 1 h, n-decanal (2.95 g, 18.89 mmol) was added and the reaction allowed to warm to 0°C. After 30 min, the reaction was quenched with water (25 mL) and diluted with ethyl acetate (25 mL). The organic layer was washed with sat'd sodium chloride (30 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 25% ethyl acetate/hexane gave 1.69 g (6.07 mmol, 64%) of product: Η NMR (500 MHz): δ 7.45 (d, J=8.0 Hz, IH), 7.21 (d, J=7.8 Hz, IH), 7.14 (s, IH), 4.88-4.94 (m, IH), 4.64 (s, 2H), 2.34 (s, 3H), 1.22-1.80 (m, 16H), 0.87 (t, J=7.0 Hz, 3H).
Step C: 3-Methyl-4-decanoyl benzaldehyde
Dess-Martin periodinane (1.00 g, 2.37 mmol) was added to a solution of 4-(l-hydroxydec-l-yl)-3-methylbenzyl alcohol (0.300 g, 1.07 mmol, from Step B) in methylene chloride (5.0 mL). After 20 min, the reaction was filtered and concentrated in vacuo. Silica gel chromatography eluting with 5% ethyl acetate/hexane gave 0.24 g (0.89 mmol, 83%) of product: Η NMR (500 MHz) δ 10.0 (s, IH), 7.76 (d, J=7.8 Hz, IH), 7.74 (s, IH), 7.66 (d, J=7.8 Hz, IH), 2.87 (t, J=7.5 Hz, 2H), 2.51 (s, 3H), 1.66-1.74 (m, 2H), 1.22-1.38 (m, 12H), 0.87 (t, J=7.0 Hz, 3H).
Aldehyde 74
3-Methyl-4-(4-(nonyl)benzoyl)benzaldehyde
The title compound was prepared using procedures analogous to those used to prepare Aldehyde 73 substituting 4-(nonyl)benzaldehyde for n-decanal in Step B: lH NMR (500 MHz) δ 10.0 (s, IH), 7.76 (d, J=7.8 Hz, IH), 7.74 (s, IH), 7.66 (d, J=7.8 Hz, IH), 2.88 (t, J=7.5 Hz, 2H), 2.51 (s, 3H), 1.66-1.74 (m, 2H), 1.22-1.38 (m, 10H), 0.88 (t, J=7.0 Hz, 3H).
-Ill- Aldehyde 75
3 ' -( 1 -Hydroxyhept- 1 -yl)-4-biphenylcarboxaldehyde Step A: l-BiOmo-3-(l-hvdroxyhept-l-yl)benzene
Hexylmagnesium bromide (2.0M in THF, 3.7 mL, 7.4 mmol) was added to a solution of 3-bromobenzaldehyde (1.50g, 8.11 mmol) in tetrahydrofuran (10 mL) at -78 °C. After 10 min, the reaction was quenched by the addition of 2N hydrochloric acid (30 mL) and the product extracted into ethyl acetate (30 mL). The organic layer was washed with sat'd sodium chloride (25 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 17% ethyl acetate/hexane gave 1.42 g (5.25 mmol, 65%) of product.
Step B: 3 ' -( 1 -Hydroxyhept- 1 -yl)-4-biphenylcarboxaldehyde
To a solution of l-bromo-3-(l-hydroxyhept-l-yl)benzene (1.00 g, 3.70 mmol, from Step A), 4-formylphenylboronic acid (0.83 g, 5.55 mmol) and potassium fluoride (0.65 g, 11.10 mmol) in tetrahydrofuran (10 mL) was added palladium(H) acetate (0.016 g, 0.071 mmol) and 2-(dicyclohexylphosphino)biphenyl (0.052 g, 0.148 mmol). After stirring for 24 h at rt, the reaction was diluted with ethyl acetate (50 mL), washed with water (50 mL), sat'd sodium chloride (50 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 25% ethyl acetate/hexanes gave 0.81 g of product as a yellow oil.
Aldehyde 76
3 ' -(Heptanoyl)-4-biphenylcarboxaldehyde Step A: 1 -Bromo-3 -heptanoyl benzene Dess-Martin periodinane (4.40 g, 15% solution in methylene chloride,
1.56 mmol) was added to a solution of l-bromo-3-(l -hydroxyhept- l-yl)benzene (0.39 g, 1.42 mmol, from Aldehyde 75, Step A). After 1 h, the reaction was quenched by the addition of IN sodium hydroxide (20 mL). The aqueous layer was separated, washed with methylene chloride (20 mL) and the organic layers combined, dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with 5% ethyl acetate/hexane gave 0.30 g (1.11 mmol, 78%) of product: Η NMR (500 MHz) δ 8.08 (t, J=1.7 Hz, IH), 7.87 (d, J=7.7 Hz, IH), 7.68 (d, J=8.0 Hz, IH), 7.34 (t, J=7.9 Hz, IH), 2.93 (t, J=7.4 Hz, 2H), 1.68-1.76 (m, 2H), 1.28-1.40 (m, 6H), 0.89 (t, J=7.0 Hz, 3H).
Step B: 3 ' -(Heptanoyl)-4-biphenylcarboxaldehyde To a solution of 1 -bromo-3 -heptanoyl benzene (0.30 g, 1.11 mmol, from Step A), 4-formylphenylboronic acid (0.25 g, 1.68 mmol) and potassium fluoride (0.20 g, 3.36 mmol) in tetrahydrofuran (2.5 mL) was added palladium(H) acetate (0.006 g, 0.025 mmol) and 2-(dicyclohexylphosphino)biphenyl (0.016 g, 0.050 mmol). After stining for 3 h at 50°C, the reaction was placed onto silica gel and eluted with 10% ethyl acetate/hexanes to give 0.26 g (0.88 mmol, 80%) of product as a yellow oil: Η NMR (500 MHz) δ 8.22 (t, J=1.7 Hz, IH), 7.90-8.10 (m, 3H), 8.30 (d, J=8.0 Hz, IH), 7.99 (d, J=8.3 Hz, 2H), 7.58 (t, J=7.8 Hz, IH), 3.02 (t, J=7.4 Hz, 2H), 1.66-1.80 (m, 2H), 1.38-1.44 (m, 2H), 1.30-1.38 (m, 4H), 0.90 (t, J=7.0 Hz, 3H).
Aldehyde 77
3-(Cyclopropyloxy)-4-(nonyloxy)benzaldehyde
To a solution of 1.78 g (10.0 mmol) of 3-(cyclopropyloxy)-4- hydroxybenzaldehyde and 2.54 g(10.0 mmol) of 1-iodononane in 20 mL acetonitrile was added 3.58 g(11.0 mmol) of Cs2CO3. The sluny was stined at rt for 12 h. The reaction was quenched with 30 mL of water and extracted with ethyl acetate (50 mL x 2). The combined extractions were washed with water, dried with sodium sulfate and concentrated to a solid. Flash chromatography on a Biotage 40M cartridge using 10 % ethyl acetate/hexanes afforded 2.9 g (95%) of the title compound as a white solid. 1H NMR (500 Mhz) δ 0.87-0.91 (m, 7H), 1.30-1.90 (m, 14H), 3.85 (m, IH), 4.10 (t, J = 6.9, 2H), 6.98 (d, J = 8.2, IH), 7.48 (dd, J = 8.5, 1.8, IH), 7.77 (d, J = 1.8, IH), 9.89 (s, IH); LC-1: 4.6 min; ESI-MS 305 (M+H).
Aldehyde 78 4-(Nonylthio)benzaldehyde To a solution of 3.15 g (10.0 mmol) of l-bromo-4-(nonylthio)benzene in 50 mL anhydrous THF was slowly added 9.4 mL of n-BuLi (1.6 M in hexanes, 15 mmol) at - 50 °C. The mixture was aged at the same temperature for 1 h before the addition of 2.3 mL of anhydrous DMF. The reaction mixture was allowed to warm to 0 °C and was quenched with 2 N HCl to pH=l. The layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The combined organic layer and extractions were washed with water and concentrated to oil. Flash chromatography on a Biotage 40M cartridge using 5 % ethyl acetate/hexanes afforded 2.35 g (89%) of the title compound as light yellow oil: 1H NMR (500 MHz) δ 0.91 (t, J = 7.0, 3H), 1.30- 1.76 (m, 14H), 3.03 (t, J = 7.4, 2H), 7.37 (d, J = 8.5, 2H), 7.78 (d, J = 8.5, 2H), 9.95 (s, IH); LC-1: 4.8 min; ESI-MS 265 (M+H).
Aldehyde 79 3-(4-(Formyl)phenyl)-5-(4-phenyl-5-trifluoiOmethyl-2-thienyl)- 1 ,2,4-oxadiazole
Step A: (E/Z)-2-Phenyl-3-chloro-4A4-trifluoro-2-butanal
Phosphorous oxychloride (7.5 mL, 80 mmol) was added to 15 mL of DMF at 0 °C. The resulting mixture was warmed to rt and stined for 1 h. A solution of 5.0 g (26.6 mmol) of l,l,l-trifluoromethyl-3-phenyl-2-propanone in 1 mL of DMF was added and the resulting mixture was stined at 70 °C for 20 h. The reaction mixture was cooled to rt, poured onto 150 g of ice and stined at ambient temperature for 1 h. The quenched mixture was extracted with 200 mL of ether. The extract was washed with 200 mL of water, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (4L) as the eluant afforded 5.1 g (82%) of the title compound.
Step B: Ethyl (4-phenyl-5-trifluoromethyl)thiophene-2-carboxylate
Ethyl mercaptoacetate (2.75 mL, 25.0 mmol) was added to a suspension of 600 mg (25 mmol) of NaH in 45 mL of THF maintaining the internal temperature at 25 °C. A solution of 5.10 g (21.7 mmol) of (E/Z)-2-phenyl-3-chloro- 4,4,4-trifluoro-2-butanal (from Step A) was added and the resulting mixture was stined at rt for 20 h. The reaction was quenched with 50 mL of sat'd NHjCl and the resulting mixture was partitioned between 250 mL of ether and 100 mL of water. The organic layer was separated, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (IL), then 4:1 v/v hexanes/CH Cl2 (IL) as the eluant afforded 5.10 g (78%) of the title compound: 1H NMR (400 Mhz) δ 1.40 (t, J= 7.2, 3H), 4.39 (q, J= 7.2, 2H), 7.42 (app s, 5H), 7.74 (q, J=1.6, IH). Step C: (4-Phenyl-5~trifluoromethyl)thiophene-2-carboxylic acid
A solution of 5.10 g (17.0 mmol) of ethyl 4-phenyl-5-trifluoromethyl- thiophene-2-carboxylate (from Step B) in 20 mL of EtOH was treated with 10 mL of 5.0 N NaOH and stined at rt for 30 min. The EtOH was removed in vacuo. The residual aqueous mixture was acidified to pH 2 with 1 N HCl, then extracted with 300 mL of 1:1 v/v EtO Ac/ether. The extract was separated, dried and concentrated. Recrystallization from 200 mL of 20: 1 v/v hexanes/ether afforded 4.30 g (93%) of the title compound: 1H NMR (500 Mhz) δ 7.43 (app s, 5H), 7.84 (app s, IH); 13C NMR (CDC13, 125 Mhz) δ 121.7 (q, J= 269), 128.5, 128.6, 128.8, 132.5 (q, J= 36), 133.3, 133.8, 137.5, 144.8, 167.0.
Step D: 3-[4-(Carbomethoxy)phenyl]-5-(4-phenyl-5-trifluoromethyl-2-thienyl)- 1,2,4-oxadiazole A solution of 408 mg (1.5 mmol) of 4-phenyl-5-trifluoromethyl- thiophene-2-carboxylic acid and 1 mL of oxalyl chloride in 5 mL of CH2C12 was treated with 5 drops of DMF. The resulting mixture was stined at rt for 1 h, then concentrated. The crude acid chloride and 291 mg (1.5 mmol) of 4- (carbomethoxy)benzamidoxime were dissolved in 7 mL of 6:1 v/v xylenes/pyridine. The resulting solution was heated at 140 °C for 1 h, then cooled. The mixture was partitioned between 50 mL of 1: 1 EtO Ac/ether and 50 mL of 1 N HCl. The organic layer was separated, washed with 3 x 50 mL of 1 N HCl, 50 mL of sat'd NaHCO3, dried and concentrated. Chromatography on a Biotage 40 M cartridge using hexanes (IL), then 20:1 v/v hexanes/EtOAc (IL) as the eluant afforded 423 mg (65%) of the title compound: 1H NMR (500 Mhz) δ 3.97 (s, 3H), 7.48 (app s, 5H), 7.92 (s, IH), 8.18 (app d, J= 8.5, 2H), 8.23 (app d, J= 8.5, 2H).
Step E: 3-[4-(Hydroxymethyl)phenyl]-5-(4-phenyl-5-trifluoromethyl-2- thienyl)- 1 ,2,4-oxadiazole A solution of 390 mg (0.91 mmol) of 3-[4-(carbomethoxy)phenyl]-5-
(4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4-oxadiazole (from Step D) in 10 mL of CH2C1 at -78 °C was treated with 2.7 mL of 1.0 M DH3ALH solution in CH2C12. The resulting solution was stined cold for 1 h, then quenched with 5 mL of sat'd Rochelle salt solution. The mixture was partitioned between 100 mL CH2CI2 and 50 mL of 1 N NaOH. The organic layer was separated, dried and concentrated. Chromatography on a Biotage 40 S cartridge using 4:1 v/v hexanes/EtOAc (IL) as the eluant afforded 325 mg (89%) of the title compound: 1H NMR (500 Mhz) δ 1.80 (app s, IH), 4.80 (d, J= 4.0, 2H), 7.46-7.48 (5H), 7.52 (d, J= 8.0, 2H), 7.91 (q, J= 1.5, IH), 8.14 (d, J= 8.0, 2H).
Step F: 3-[4-(Formyl)phenyl]-5-(4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4- oxadiazole A mixture of 310 mg (0.77 mmol) of 3-[4-(hydroxymethyl)phenyl]-5-
(4-phenyl-5-trifluoromethyl-2-thienyl)-l,2,4-oxadiazole (from Step E), 527 mg (1.5 mmol) of 4-methylmorpholine N-oxide and 500 mg of 4 A molecular sieves in 15 mL of CH3CN was treated with 12 mg (0.034 mmol) of tetrapropylammonium perruthnate and the resulting mixture was stined ar rt for 2 h. The solids were filtered and the filtrated was concentrated. Chromatography on a Biotage 40 S cartridge using 9:1 v/v hexanes/EtOAc (IL) as the eluant afforded 205 mg (66%) of the title compound: 1H NMR (500 Mhz) δ 7.48 (app s, 5H), 7.93 (app s, IH), 8.03 (d, J= 8.5, 2H), 8.33 (d, J= 8.5, 2H), 10.1 (s, IH).
Aldehyde 80
4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzaldehyde
Step A: 2-Hydroxymethyl-4-phenyl-5-trifluoromethyl-thiophene A solution of 2.10 g (7.7 mmol) of 4-phenyl-5-trifluoromethyl- thiophene-2-carboxylic acid (from Aldehyde 17, Step C) in 20 mL of THF was treated with 5.0 mL of 2.0 M borane dimethylsulfide complex in THF. The resulting solution was heated at reflux for 3 h, cooled to rt, quenched with 10 mL of MeOH and concentrated. Chromatography on a Biotage 40M cartridge using 9:1 v/v hexanes/EtOAc as the eluant afforded 1.95 g (98%) of the title compound: 1H NMR (500 Mhz) δ 2.05 (app s, IH), 4.87 (s, 2H), 6.99 (s, IH), 7.41 (app s, 5H).
Step B: 4-((4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy)benzaldehvde A solution of 1.95 g (7.5 mmol) of 2-hydroxymethyl-4-phenyl-5- trifluoromethyl-thiophene (from Step A), 925 mg (7.6 mmol) of 4- hydroxybenzaldehyde and 3.0 g (11.4 mmol) of triphenylphosphene in 40 mL of THF at 0 °C was treated with 2.0 g (11.4 mmol) of diethylazodicarboxylate. The resulting mixture was warmed to rt, stined for 2 h, then concentrated. Chromatography on a Biotage 75S cartridge using 9:1 v/v heptane/EtOAc as the eluant afforded 2.5 g of impure title compound. Chromatography on a Biotage 40M cartridge using 19:1 v/v hexanes/EtOAc (IL), then 4:1 v/v hexanes/EtOAc (IL) as the eluant afforded 1.65 g (60%) of the title compound: !H NMR (500 Mhz) δ 5.32 (s, 2H), 7.10 (d, J= 8.5, 2H), 7.12 (s, IH), 7.41-7.43 (5H), 7.85-7.90 (2H), 9.92 (s, IH).
PREPARATION OF EXAMPLES
EXAMPLE 1
N-((4-Decyloxy)benzyl)-3 -aminopropylphosphonic acid 3-Aminopropylphosphonic acid (0.064 g, 0.457 mmol) and tetrabutylammonium hydroxide (1.0M in methanol, 0.46 mL, 0.46 mmol) in methanol (3 mL) were heated at 50 °C for 1 h to dissolve all solids. 4-(Decyloxy)benzaldehyde (O.lOOg, 0.381 mmol) and sodium cyanoborohydride (0.025 g, 0.40 mmol) were added and stirring was continued for 1 h at 50 °C. The reaction mixture was made acidic (pH~5) by the addition of concentrated HCl then directly purified by LC-3 to give the title compound (0.055 g): Η NMR (500 MHz , CD3OD) δ 7.39 (d, J=8.7 Hz, 2H), 6.98 (d, J=8.7 Hz, 2H), 4.12 (s, 2H), 3.99 (t, J=6.4 Hz, 2H), 3.12 (t, J=7.7 Hz, 2H), 2.0 (m, 2H), 1.64-1.84 (m, 4H), 1.47 (m, 2H), 1.24-1.40 (m, 12H), 0.90 (t, J=6.9 Hz, 3H); MS m/e 386.4 (M+H).
EXAMPLES 2-107 The following Examples (2-112) were prepared using a procedure analogous to that described in EXAMPLE 1 substituting A for 4-(decyloxy)benzaldehyde and B for 3- aminopropylphosphonic acid.
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
(m,
(m,
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
(m,
(s,
(m,
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
EXAMPLE 108 (R S)-3-(N-(4-Nonylbenzyl)amino-l-hvdroxypropylphosphonic acid Step A: (R/S)-Diethyl 3-benzyIoxycarbonylamino-l-hydroxypropylphosphonate
To a solution of potassium bis(trimethylsilyl)amide (1.13g, 5.66 mmol) in tetrahydrofuran (10 mL) at 0 °C was added diethyl phosphite (0.73 g, 5.66 mmol). After 10 min, 3-(benzyloxycarbonylamino)propanal (0.78 g, 3.77 mmol) was added as a solution in tetrahydrofuran (5 mL). After 30 min, the reaction was quenched by the addition of 2N hydrochloric acid (25 mL) and extracted with ethyl acetate (50 mL). The organic layer was washed with sat'd sodium chloride (50 mL), dried over magnesium sulfate and concentrated in vacuo. Silica gel chromatography eluting with hexane/acetone (1:1) gave a colorless oil (0.36 g): ESI-MS 346.1 (M+H).
Step B: (R/S)-Diethyl 3-amino-l-hydroxypropylphosphonate (R/S)-Diethyl 3-benzyloxycarbonylamino-l- hydroxypropylphosphonate (0.36 g, 1.04 mmol, from Step A) and palladium on carbon (10%, 0.10 g) were stined together in methanol (5 mL) under an atmosphere of hydrogen. After 2 h, the reaction was filtered and concentrated in vacuo to give a colorless oil: Η NMR (500 MHz , CD3OD) δ 4.10-4.22 (m, 4H), 4.00-4.05 (m, IH), 2.85-3.00 (m, 2H), 1.85-2.00 (m, 2H), 1.34 (t, J=7.0 Hz, 6H); ESI-MS 211.8 (M+H)
Step: C (R/S)-Diethyl 3-(N-(4-nonylbenzyl)amino-l-hydroxypropylphosphonate
(R S)-Diethyl 3-amino-l-hydroxypropylphosphonate (0.030 g, 0.142 mmol, from Step C), 4-nonylbenzaldehyde (0.036 g, 0.142 mmol) and sodium cyanoborohydride (0.004 g, 0.071 mmol) in methanol (1.5 mL) were heated at 50°C for 3 h. The reaction was made acidic (ρH~5) by the addition of concentrated hydrochloric acid then directly purified by LC-3 to give a colorless oil (0.031 g).
Step D: (R/S)-3-(N-(4-nonylbenzyl)amino- 1-hvdroxypropylphosphonic acid (R/S)-Diethyl 3-(N-(4-nonylbenzyl)amino-l-hydroxypropylphosphonate (0.031 g) was dissolved in acetonitrile (1 mL) and treated with bromotrimethylsilane (0.050 mL, 0.362 mmol). After stirring for 1 h at 50°C, the reaction was quenched with methanol (1 mL), stined for 30 min then concentrated. The residue was purified via HPLC to give desired product (0.011 g): Η NMR (500 MHz , CD3OD) δ 7.39 (d, J=8.3 Hz, 2H), 7.28 (d, J=8.3 Hz, 2H), 4.16 (s, 2H), 3.87-3.92 (m, IH), 3.18-3.34 (m, 2H), 2.64 (t, J=7.7 Hz, 2H), 2.04-2.20 (m, 2H), 1.58-1.64 (m, 2H), 1.24-1.34 (m, 12H), 0.89 (t, J=7.0 Hz, 3H); ESI-MS 372.2 (M+H).
EXAMPLES 109-111 The following EXAMPLES (109-111) were made according to the procedure described for EXAMPLE 108 substituting A for 4-nonylbenzaldehyde and the diethyl ester of B for (R/S)-diethyl 3-amino-l-hydroxyphosphonate in Step C.
Figure imgf000141_0001
Figure imgf000142_0001
EXAMPLE 112 N-(4-Nonylbenzyl)-3-aminopropylphosphonic acid 3-Aminopropylphosphonic acid (0.060 g, 0.436 mmol) and tetrabutylammonium hydroxide (l.OM in methanol, 0.44 mL, 0.43 mmol) in methanol (3 mL) were heated at 50°C for 15 min until all of the solids had dissolved. 4- (Nonyl)benzyliodide (0.100 g, 0.291 mmol) and DIEA (0.112 g, 0.872 mmol) were added and stirring was continued for 12 h at 50 °C. The reaction was made acidic (pH~5) by the addition of concentrated hydrochloric acid then directly purified using LC-3 to give the title compound (0.020 g): Η NMR (500 MHz , CD3OD) δ 7.39 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 4.15 (s, 2H), 3.14 (t, J=7.6 Hz, 2H), 2.64 (t, J=7.7 Hz, 2H), 2.00 (m, 2H), 1.79 (td, J=5.3, 18.5 Hz, 2H), 1.61 (m, 2H), 1.24-1.36 (m, 14H), 0.89 (t, J=7.0 Hz, 3H); ESI-MS 356.2 (M+H).
EXAMPLE 113 3-r(4-Octylbenzyl)amino1propylphosphinic acid Step A: Ethyl 2-cyanoethyl(diethoxymethyl)phosphinate To a solution 2.6234 g (13.37 mmol) of ethyldiethoxymethyl phosphinate in 10 mL EtOH was added 0.5670 g (10.70 mmol) acrylonitrile. The resulting mixture was added to a solution of 0.071 g (2.81 mmol) NaH in 10 mL EtOH at 0 °C. The ice bath was removed at the end of the addition, and the reaction mixture was stirred at rt for 16 hr. The mixture was neutralized (pH = 7) with HOAc, and was partitioned between EtOAc and H2O. The organic layer was separated, dried and concentrated, which provided 2.47 g (93% yield) of the title compound: 1H NMR (500 MHz) δ 1.25 (t, J = 6.9, 6H), 1.34 (t, J = 7.1, 3H), 2.11-2.19 (m, 2H), 2.68-2.74 (m, 2H), 3.62-3.73 (m, 2H), 3.80-3.87 (m, 2H), 4.13-4.25 (m, 2H), 4.70 (d, J = 6.4, IH); ESI-MS 250 (M+H).
Step B: Ethyl 3-Aminopropyl(diethoxymethyl)phosphinate
To a solution of 2.47 g (9.91 mmol) of ethyl 2-cyanoethyl (diethoxymethyl)phosphinate (from Step A) in 20 mL 2.0 M ammonia in EtOH was added 250 mg Raney Nickel. The mixture was subjected to hydrogenation conditions (H2, 40 psi, rt) for 16 hr. The reaction mixture was filtered over Celite and partitioned between CH2CI2 and H2O. The aqueous phase was extracted twice with CH2CL2. The organic layer and extractions were combined, dried, and concentrated to provide 2.13 g (85% yield) of the title compound: 1H NMR (500 MHz) δ 1.23 (dt, = 7.1, J2 = 1.6 6H), 1.29 (t, J = 7.1, 3H), 1.42 (s, br, 2H), 1.71-1.82 (m, 4H), 2.72-2.75 (m, 2H), 3.63-3.70 (m, 2H), 3.78-3.86 (m, 2H), 4.08-4.21 (m, 2H), 4.64 (d, J = 6.7, IH); ESI- MS 254 (M+H).
Step C: 3-r(4-Octylbenzyl aminolpropylphosphinic acid A mixture of 98.5 mg (0.389 mmol) of ethyl 3-aminopropyl
(diethoxymethyl)phosphinate (from Step B) and 84.9 mg (0.389 mmol) of 4- octylbenzaldehyde in 1 mL of MeOH at rt was treated with 12.2 mg (0.194 mmol) Na(CN)BH3. The resulting reaction mixture was stined at rt for 16 hr. The reaction was quenched with 0.5 mL of 12 N HCl, then heated up to 80 °C for 1 hr. The mixture was cooled and concentrated. HPLC purification (LC-2) afforded 60 mg (47%) of the title compound: 1H NMR (500 MHz, CD3OD) δ 0.88 (t, J = 7.1, 3H), 1.25-1.33 (m, 10H), 1.59-1.66 (m, 4H), 1.90-1.96 (m, 2H), 2.63 (t, J = 7.7, 2H), 3.09 (t, J = 6.9, 2H), 4.12 (s, 2H), 7.03 (d, J = 505.6, IH), 7.27 (d, J = 8.0, 2H), 7.38 (d, J = 8.0, 2H); LC- 1: 3.02 min; ESI-MS 326 (M+H).
EXAMPLES 114-116
Figure imgf000144_0001
The following compounds were prepared using procedures analogous to those described in EXAMPLE 113 substituting the appropriate Aldehyde for 4- oct lbenzaldeh de in Ste C.
Figure imgf000144_0002
EXAMPLE 117 3-(N-(4-(4-Pentyl)biphenylmethyl))aminopropylphosphinic acid The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting Aldehyde 56 for 4-octylbenzaldehyde in Step C: LC-1: 2.86 min; ESI-MS 360 (M+H).
EXAMPLE 118 3-(N-(4-(4-Heptyloxy)biphenylmethyl) aminopropylphosphinic acid The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting Aldehyde 51 for 4-octylbenzaldehyde in Step C: LC-1: 3.06 min; ESI-MS 404 (M+H).
EXAMPLE 119 3-N-(3-Bromo-5-methoxy-4-(octyloxy)benzyl)aminopropylphosphinic acid The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting Aldehyde 13 for 4-octylbenzaldehyde in Step C: LC-1: 2.98 min; ESI-MS 450 (M+H).
EXAMPLE 120
3-N-(3-Fluoro-4-(nonyloxy)benzyl)aminopropylphosphinic acid The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting 3-fluoro-4-(nonyloxy)benzaldehyde for 4- octylbenzaldehyde in Step C: 1H NMR (500 Mhz) δ 0.91 (t, 7=7.0, 3H), 1.30-1.40 (m, 10H), 1.48-1.51 (m, 2H), 1.71-1.99 (m, 6H), 3.11 (t, 7=7.2, 2H), 4.07 (t, 7=6.4, 2H), 4.12 (s, 2H), 7.06 (d, 7=519, IH), 7.13-7.29 (m, 3H); LC-1: 2.96 min; ESI-MS 374 (M+H).
EXAMPLE 121
3-N-(2-Chloro-4-(nonyloxy)benzyl)aminopropylphosphinic acid The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting 2-chloro-4-(nonyloxy)benzaldehyde for 4-octylbenzaldehyde in Step C: LC-1 : 3.07 min; ESI-MS 390 (M+H).
EXAMPLE 122 3-N-(6-Heptyloxy)napthylmethyl)aminopropylphosphinic acid
The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting 6-heptyloxy- 1 -napthaldehyde for 4-octylbenzaldehyde in Step C: LC-1: 2.90 min; ESI-MS 378 (M+H).
EXAMPLE 123 3-(N-(3-Cyclopropyloxy-4-(nonyloxy)benzyl)amino)propylphosphinic acid
The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting Aldehyde 77 for 4-octylbenzaldehyde in Step C: LC-1: 3.04 min; ESI-MS 412 (M+H).
EXAMPLE 124 3-(N-(4-(Nonylthio)benzyl)amino)propylphosphinic acid
The title compound was using a procedure analogous to that described in EXAMPLE 113, substituting Aldehyde 78 for 4-octylbenzaldehyde in Step C: 1H NMR (500 Mhz) (CD3OD) δ 0.90 (t, J = 7.0, 3H), 1.30-1.32 (m, 10H), 1.43-1.46 (m, 2H), 1.63-1.66 (m, 2H), 1.78-1.83 (m, 2H), 1.95-1.99 (m, 2H), 2.98 (t, J = 7.2, 2H), 3.14 (t, J = 7.5, 2H), 4.16 (s, 2H), 7.08 (d, J = 533, IH), 7.37-7.42 (m, 4H); LC-1: 3.10 min; ESI-MS 372 (M+H).
EXAMPLE 125
Ethyl (3-(4-nonylbenzyl)amino)propylphosphinic acid A solution of 88 mg (0.26 mmol) of 3-((4-nonylbenzyl)amino)propylphosphinic acid (from EXAMPLE 114) in 1 mL N,N-bis(trimethylsilyl)amine was heated to 100 °C for 8 hr. Upon cooling to rt, 81.1 mg (0.52 mmol) of iodoethane was added, followed by the addition of 67.2 mg (0.52 mmol) of DIEA. The resulting mixture was heated to 60 °C overnight. The reaction mixture was cooled and concentrated. HPLC purification (LC-2) afforded 12 mg (13%) of the title compound. 1H NMR (500 MHz) (CD3OD) 8 0.88 (t, J = 7.1, 3H), 1.09-1.18 (m, 3H), 1.26-1.31 (m, 12H), 1.59-1.75 (m, 6H), 1.94-2.00 (m, 2H), 2.63 (t, J = 7.6, 2H), 3.10 (t, J = 6.9, 2H), 4.13 (s, 2H), 7.27 (d, J = 8.0, 2H), 7.39 (d, J = 8.0 2H); LC-1: 2.92 min; ESI-MS 368 (M+H).
EXAMPLES 126-127
Figure imgf000146_0001
The following compounds were prepared a procedure analogous to that described in EXAMPLE 125 substituting the appropriate alkyl halide for ethyl iodide.
Figure imgf000147_0002
EXAMPLE 128 Hydroxymethyl (3-(4-nonylbenzyl)amino)propylphosphinic acid
A solution of 71 mg (0.21 mmol) of 3-(4- nonylbenzyl)aminopropylphosphinic acid (from EXAMPLE 114) in 1 mL of N,N- (trimethylsilyl)amine was heated to 100 °C for 8 hr. Upon cooling to rt, 15.8 mg (0.53 mmol) of paraformaldehyde was added. The resulting mixture was heated at 30 °C for 3 hr, and stined at rt under nitrogen for 16 hr. The reaction mixture concentrated. HPLC purification (LC-2) afforded 22 mg (28%) of the title compound. 1H NMR (500 MHz) (CD3OD) δ 0.88 (t, J = 7.1, 3H), 1.27-1.31 (m, 12H), 1.57-1.63 (m, 2H), 1.80-1.85 (m, 2H), 1.97-2.05 (m, 2H), 2.63 (t, J = 7.8, 2H), 3.12 (t, J = 6.9, 2H), 3.70 (d, J = 6.2, 2H), 4.13 (s, 2H), 7.27 (d, J = 8.0, 2H), 7.39 (d, J = 8.2, 2H); LC-1: 2.90 min; ESI-MS 370 (M+H).
EXAMPLES 129-133
Figure imgf000147_0001
The following compounds were prepared using a procedure analogous to that described in EXAMPLE 128 substituting the appropriate aldehyde for paraformaldehyde.
Figure imgf000148_0001
EXAMPLE 134 Hydroxymethyl (3-(4-octylbenzyl)amino)propyIphosphinic acid
The title compound was prepared from 3-(4- octylbenzyl)aminopropylphosphinic acid (from EXAMPLE 114) using a procedure analogous to that described in EXAMPLE 128: LC-1: 2.67 min; ESI-MS 356 (M+H). EXAMPLE 135
Hydroxymethyl 3-(3-(cvclopropyloxy)-4-(nonyloxy)benzyl)aminopropylphosphinic
acid
The title compound was prepared from 3-(3-(cyclopropyloxy)-4- (nonyloxy)benzyl)aminopropylphosphinic acid (from EXAMPLE 123) using a procedure analogous to that described in EXAMPLE 128: LC-1: 2.95 min; ESI-MS 442 (M+H).
EXAMPLE 136
Hydroxymethyl 3-(3-fluoro-4-(nonyloxy)benzyl aminopropylphosphinic acid
The title compound was prepared from 3-(3-fluoro-4-(nonyloxy)benzyl)amino- propylphosphinic acid (from EXAMPLE 125) using a procedure analogous to that described in EXAMPLE 128: LC-1: 2.87 min; ESI-MS 404 (M+H).
EXAMPLE 137
Ethoxycarbonyl 3-(N-(4-(4-heptyloxy)biphenylmethyl))aminopropylphosphinic acid
To a solution of 32.5 mg (0.081 mmol) of 3-(N-(4-(4'- heptyloxy)biphenylmethyl)) aminopropylphosphinic acid (from EXAMPLE 118) in 2 mL dichloromethane was added 0.1 mL of TMSCl and 0.12 mL of DIEA at 0 °C. The solution was stined at rt for an additional one hour and 0.1 mL of ethyl chloroformate (0.81 mmol) was added. The reaction was quenched with MeOH and concentrated to oil. The product was isolated and purified by LC-2: 1H NMR (500 Mhz) (CD3OD) δ 0.94 (t, J = 6.9, 3H), 1.31-1.43 (m, 8H), 1.51-1.53 (m, 2H), 1.80-1.83 (m, 2H), 1.89- 1.92 (m, 2H), 2.03-2.06 (m, 2H), 3.18 (t, J = 6.7, 2H), 4.05 (t, J = 6.4, 2H), 4.24 (s, 2H), 4.25 (q, J =7.0, 2H), 6.95-7.72 (m, 8H); LC-1: 3.26 min; ESI-MS 476 (M+H). EXAMPLE 138
3-(4-Octylbenzyl)amino-2-phenylpropylphosphinic acid
A mixture of 69.2 mg (0.210 mmol) of ethyl 3-amino-2- phenylpropyl(diethoxymethyl)phosphinate (Tetrahedron, 1989, 3787-3808) and 48.2 mg (0.221 mmol) of 4-octylbenzaldehyde in 1 mL of MeOH at rt was treated with 6.7 mg (0.105 mmol) of Na(CN)BH3. The resulting reaction mixture was stined at rt for 16 hr. The reaction was quenched with 0.3 mL of 12 N HCl, then heated up to 60 °C for 5 hr. The mixture was cooled and concentrated. HPLC purification (LC-2) afforded 22 mg (26%) of the title compound. 1H NMR (500 MHz) (CD3OD) δ 0.88 (t, J = 7.1, 3H), 1.26-1.30 (m, 10H), 1.58-1.61 (m, 2H), 2.01-2.17 (m, 2H), 2.62 (t, J = 7.8, 2H), 3.20-3.23 (m, lH),3.35-3.46 (m, 2H), 4.11 (s, 2H), 6.92 (d, J = 525.4, IH), 7.23-7.37 (m, 9H); LC-1: 3.31 min; ESI-MS 402 (M+H).
EXAMPLE 139
3-(3-Bromo-5-methoxy-4-(octyloxy)benzyl)amino-2-phenylpropylphosphinic acid
The title compound was prepared using a procedure analogous to that described in EXAMPLE 138 substituting Aldehyde 13 for 4-octylbenzaldehyde: LC- 1: 3.51 min; ESI-MS 526 (M+H).
EXAMPLES 140-150
The following compounds were prepared using a procedure analogous to that described in EXAMPLE 1 substituting the appropriate aminoalkylcarboxylic acid or aminoalkylphosphonic acid for 3-aminopropylphosphonic acid and either Aldehyde 79 or 80 for 4-(decyloxy)benzaldehyde. The products were purified using LC-2.
Figure imgf000151_0001
Figure imgf000151_0002
Figure imgf000152_0001
BIOLOGICAL ACTIVITY
The SlPi/Edgl, SlP3,/Edg3, SlP2/Edg5, SIP Εdgό or SIP5 /Edg8 activity of the compounds of the present invention can be evaluated using the following assays:
Ligand Binding to Edg/SIP Receptors Assay 33p-sρhingosine-l-phosphate was synthesized enzymatically from γ33p_ATP and sphingosine using a crude yeast extract with sphingosine kinase activity in a reaction mix containing 50 mM KH2PO4, 1 mM mercaptoethanol, 1 mM Na3VO4, 25 mM KF, 2 mM semicarbazide, 1 mM Na2EDTA, 5 mM MgCl2, 50 mM sphingosine, 0.1% TritonX-114, and 1 mCi γ33p_ATP (NEN; specific activity 3000 Ci/mmol). Reaction products were extracted with butanol and 33p_Sp ingosine-l- phosphate was purified by HPLC.
Cells expressing EDG/S1P receptors were harvested with enzyme-free dissociation solution (Specialty Media, Lavallette, NJ). They were washed once in cold PBS and suspended in binding assay buffer consisting of 50 mM HEPES-Na, pH 7.5, 5mM MgCl2, ImM CaCl2, and 0.5% fatty acid-free BSA. 33p-Sphingosine-l- phosphate was sonicated with 0.1 nM sphingosine- 1-phosphate in binding assay buffer; 100 μl of the ligand mixture was added to 100 μl cells (1 x lθ6 cells/ml) in a 96 well microtiter dish. Binding was performed for 60 min at room temperature with gentle mixing. Cells were then collected onto GF/B filter plates with a Packard Filtermate Universal Harvester. After drying the filter plates for 30 min, 40 μl of Microscint 20 was added to each well and binding was measured on a Wallac Microbeta Scintillation Counter. Non-specific binding was defined as the amount of radioactivity remaining in the presence of 0.5 μM cold sphingosine- 1-phosphate. Alternatively, ligand binding assays were performed on membranes prepared from cells expressing Edg/SIP receptors. Cells were harvested with enzyme-free dissociation solution and washed once in cold PBS. Cells were disrupted ' by homogenization in ice cold 20 mM HEPES pH 7.4, 10 mM EDTA using a Kinematica polytron (setting 5, for 10 seconds). Homogenates were centrifuged at 48,000 x g for 15 min at 40C and the pellet was suspended in 20 mM HEPES pH 7.4, 0.1 mM EDTA. Following a second centrifugation, the final pellet was suspended in 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2- Ligand binding assays were performed as described above, using 0.5 to 2 μg of membrane protein.
Agonists and antagonists of Edg/SIP receptors can be identified in the 3p-Sphingosine- 1-phosphate binding assay. Compounds diluted in DMSO, methanol, or other solvent, were mixed with probe containing 33p_sphingosine-l- phosphate and binding assay buffer in microtiter dishes. Membranes prepared from cells expressing Edg/SIP receptors were added, and binding to 33p_Sp ingosine-l- phosphate was performed as described. Determination of the amount of binding in the presence of varying concentrations of compound and analysis of the data by nonlinear regression software such as MRLCalc (Merck Research Laboratories) or PRISM (GraphPad Software) was used to measure the affinity of compounds for the receptor. Selectivity of compounds for Edg/S IP receptors was determined by measuring the level of 33p_Sp ingosine-l-phosphate binding in the presence of the compound using membranes prepared from cells transfected with each respective receptor (SlPi/Edgl, SlP3/Edg3, SlP2/Edg5, SIP Εdgό, SlP5/Edg8).
35s-GTPγS Binding Assay
Functional coupling of SlP/Edg receptors to G proteins was measured in a 35s-GTPγS binding assay. Membranes prepared as described in the Ligand Binding to Edg/S IP Receptors Assay (1-10 μg of membrane protein) were incubated in a 200 μl volume containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2,
5 μM GDP, 0.1% fatty acid-free BSA (Sigma, catalog A8806), various concentrations of sphingosine- 1-phosphate, and 125 pM 35s-GTPγS (NEN; specific activity 1250 Ci/mmol) in 96 well microtiter dishes. Binding was performed for 1 hour at room temperature with gentle mixing, and terminated by harvesting the membranes onto GF/B filter plates with a Packard Filtermate Universal Harvester. After drying the filter plates for 30 min, 40 μl of Microscint 20 was added to each well and binding was measured on a Wallac Microbeta Scintillation Counter.
Agonists and antagonists of SlP/Edg receptors can be discriminated in the 35s-GTPγS binding assay. Compounds diluted in DMSO, methanol, or other solvent, were added to microtiter dishes to provide final assay concentrations of 0.01 nM to 10 μM. Membranes prepared from cells expressing SlP/Edg receptors were added, and binding to 35s-GTPγS was performed as described. When assayed in the absence of the natural ligand or other known agonist, compounds that stimulate 35s- GTPγS binding above the endogenous level were considered agonists, while compounds that inhibit the endogenous level of 35s-GTPγS binding were considered inverse agonists. Antagonists were detected in a 35s-GTPγS binding assay in the presence of a sub-maximal level of natural ligand or known SlP/Edg receptor agonist, where the compounds reduced the level of 35s-GTPγS binding. Determination of the amount of binding in the presence of varying concentrations of compound was used to measure the potency of compounds as agonists, inverse agonists, or antagonists of SlP/Edg receptors. To evaluate agonists, percent stimulation over basal was calculated as binding in the presence of compound divided by binding in the absence of ligand, multiplied by 100. Dose response curves were plotted using a non-linear regression curve fitting program MRLCalc (Merck Research Laboratories), and EC50 values were defined to be the concentration of agonist required to give 50% of its own maximal stimulation. Selectivity of compounds for SlP/Edg receptors was determined by measuring the level of 35s-GTPγS binding in the presence of compound using membranes prepared from cells transfected with each respective receptor.
Intracellular Calcium Flux Assay
Functional coupling of SlP/Edg receptors to G protein associated intracellular calcium mobilization was measured using FLIPR (Fluorescence Imaging Plate Reader, Molecular Devices). Cells expressing S lP/Edg receptors were harvested and washed once with assay buffer (Hanks Buffered Saline Solution (BRL) containing 20mM HEPES, 0.1% BSA and 710 μg/ml probenicid (Sigma)). Cells were labeled in the same buffer containing 500 nM of the calcium sensitive dye Fluo-4 (Molecular Probes) for 1 hour at 370C and 5% CO2- The cells were washed twice with buffer before plating 1.5xlθ5 per well (90μl) in 96 well polylysine coated black microtiter dishes. A 96-well ligand plate was prepared by diluting sphingosine- 1- phosphate or other agonists into 200 μl of assay buffer to give a concentration that was 2-fold the final test concentration. The ligand plate and the cell plate were loaded into the FLIPR instrument for analysis. Plates were equilibrated to 370C. The assay was initiated by transferring an equal volume of ligand to the cell plate and the calcium flux was recorded over a 3 min interval. Cellular response was quantitated as area (sum) or maximal peak height (max). Agonists were evaluated in the absence of natural ligand by dilution of compounds into the appropriate solvent and transfer to the Fluo-4 labeled cells. Antagonists were evaluated by pretreating Fluo-4 labeled cells with varying concentrations of compounds for 15 min prior to the initiation of calcium flux by addition of the natural ligand or other S lP/Edg receptor agonist. Preparation of Cells Expressing SlP/Edg Receptors
Any of a variety of procedures may be used to clone SlPχ/Edgl, SlP3/Edg3, SlP2/Edg5, SlP4/Edg6 or SlP5/Edg8. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence; (2) direct functional expression of the Edg/SIP cDNA following the construction of an S lP/Edg-containing cDNA library in an appropriate expression vector system; (3) screening an SlP/Edg-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the SlP/Edg protein; (4) screening an SlP/Edg-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the SlP/Edg protein. This partial cDNA is obtained by the specific PCR amplification of SlP/Edg DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other proteins which are related to the SlP/Edg protein; (5) screening an SlP Edg-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a mammalian SlP/Edg protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of SlP Edg cDNA; or (6) designing 5' and 3' gene specific oligonucleotides using the SlP/Edg nucleotide sequence as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding SlP/Edg.
It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types-or species types, may be useful for isolating an SlP/Edg-encoding DNA or an SlP/Edg homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells.
It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have SlP/Edg activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding SlP/Edg may be done by first measuring cell-associated SlP/Edg activity using any known assay available for such a purpose.
Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene. An expression vector containing DNA encoding an SlP Edg-like protein may be used for expression of SlP/Edg in a recombinant host cell. Such recombinant host cells can be cultured under suitable conditions to produce SlP/Edg or a biologically equivalent form. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Commercially available mammalian expression vectors may be suitable for recombinant SlP/Edg expression.
Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as E. coli, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells including but not limited to Drosophila and silkworm derived cell lines.
The nucleotide sequences for the various SlP/Edg receptors are known in the art. See, for example, the following: SlPi/Edgl Human Hla, T. and T. Maciag 1990 An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein coupled receptors. J. Biol Chem. 265:9308-9313, hereby incorporated by reference in its entirety.
WO91/15583, published on October 17, 1991, hereby incorporated by reference in its entirety.
WO99/46277, published on September 16, 1999, hereby incorporated by reference in its entirety. SlPi/Edgl Mouse
WO0059529, published October 12, 2000, hereby incorporated by reference in its entirety.
U.S. No. 6,323,333, granted November 27, 2001, hereby incorporated by reference in its entirety. SlPi/Edgl Rat
Lado, D.C, C. S. Browe, A.A. Gaskin, J. M. Borden, and A. J. MacLennan. 1994 Cloning of the rat edg-1 immediate-early gene: expression pattern suggests diverse functions. Gene 149: 331-336, hereby incorporated by reference in its entirety.
U.S. No. 5,585,476, granted December 17, 1996, hereby incorporated by reference in its entirety.
U.S. No. 5856,443, granted January 5, 1999, hereby incorporated by reference in its entirety.
SlP3_/Edg3 Human
An, S., T. Bleu, W. Huang, O.G. Hallmark, S. R. Coughlin, E.J. Goetzl 1997 Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids FEBS Lett. 417:279-282, hereby incorporated by reference in its entirety.
WO 99/60019, published November 25, 1999, hereby incorporated by reference in its entirety.
U.S. No. 6,130,067, granted October 10, 2000, hereby incorporated by reference in its entirety.
SlP3_/Edg3 Mouse
' ^ WO 01/11022, published February 15, 2001, hereby incorporated by reference in its entirety.
SlP3/Εdg3 Rat
WO 01/27137, published April 19, 2001, hereby incorporated by reference in its entirety. SlP? Edg5 Human
An, S., Y. Zheng, T. Bleu 2000 Sphingosine 1-Phosphate-induced cell proliferation, survival, and related signaling events mediated by G Protein-coupled receptors Edg3 and Edg5. J. Biol. Chem 275: 288-296, hereby incoφorated by reference in its entirety.
WO 99/35259, published July 15, 1999, hereby incoφorated by reference in its entirety.
WO99/54351, published October 28, 1999, hereby incoφorated by reference in its entirety.
WO 00/56135, published September 28, 2000, hereby incoφorated by reference in its entirety.
SlP?/Edg5 Mouse WO 00/60056, published October 12, 2000, hereby incoφorated by reference in its entirety.
SlP2/Edg5 Rat
Okazaki, H., N. Ishizaka, T. Sakurai, K. Kurokawa, K. Goto, M. Kumada, Y. Takuwa 1993 Molecular cloning of a novel putative G protein-coupled receptor expressed in the cardiovascular system. Biochem. Biophys. Res. Comm. 190: 1104-1109, hereby incoφorated by reference in its entirety.
MacLennan, A.J., C. S. Browe, A.A. Gaskin, D.C. Lado, G. Shaw 1994 Cloning and characterization of a putative G-protein coupled receptor potentially involved in development. Mol. Cell. Neurosci. 5: 201-209, hereby incoφorated by reference in its entirety.
U.S. No. 5,585,476, granted December 17, 1996, hereby incoφorated by reference in its entirety.
U.S. No. 5856,443, granted January 5, 1999, hereby incoφorated by reference in its entirety. SlP4/Edg6 Human
Graler, M.H., G. Bernhardt, M. Lipp 1998 EDG6, a novel G-protein- coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in Iymphoid tissue. Genomics 53: 164-169, hereby incoφorated by reference in its entirety.
WO 98/48016, published October 29, 1998, hereby incoφorated by reference in its entirety.
U.S. No. 5,912,144, granted June 15, 1999, hereby incoφorated by reference in its entirety. WO 98/50549, published November 12, 1998, hereby incoφorated by reference in its entirety.
U.S. No. 6,060,272, granted May 9, 2000, hereby incoφorated by reference in its entirety.
WO 99/35106, published July 15, 1999, hereby incoφorated by reference in its entirety.
WO 00/15784, published March 23, 2000, hereby incoφorated by reference in its entirety.
WO 00/14233, published March 16, 2000, hereby incoφorated by reference in its entirety.
SlP4/Edg6 Mouse
WO 00/15784, published March 23, 2000, hereby incoφorated by reference in its entirety.
SlP^/Edgδ Human
Im, D.-S., J. Clemens, T.L. Macdonald, K.R. Lynch 2001 Characterization of the human and mouse sphingosine 1-phosphate receptor, SIP5
(Edg-8): Structure-Activity relationship of sphingosine 1-phosphate receptors. Biochemistry 40:14053-14060, hereby incoφorated by reference in its entirety. WO 00/11166, published March 2, 2000, hereby incoφorated by reference in its entirety. WO 00/31258, published June 2, 2000, hereby incoφorated by reference in its entirety.
WO 01/04139, published January 18, 2001, hereby incoφorated by reference in its entirety. EP 1 090 925, published April 11 , 2001 , hereby incoφorated by reference in its entirety.
SlPj/Edg8 Rat
Im, D.-S., CE. Heise, N. Ancellin, B. F. O'Dowd, G.-J. Shei, R. P. Heavens, M. R. Rigby, T. Hla, S. Mandala, G. McAllister, S.R. George, K.R. Lynch 2000 Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem. 275: 14281-14286, hereby incoφorated by reference in its entirety.
WO 01/05829, published January 25, 2001, hereby incoφorated by reference in its entirety.
Measurement of cardiovascular effects
The effects of compounds of the present invention on cardiovascular parameters can be evaluated by the following procedure:
Adult male rats (approx. 350 g body weight) were instrumented with femoral arterial and venous catheters for measurement of arterial pressure and intravenous compound administration, respectively. Animals were anesthetized with Nembutal (55 mg/kg, ip). Blood pressure and heart rate were recorded on the Gould Po-Ne-Mah data acquisition system. Heart rate was derived from the arterial pulse wave. Following an acclimation period, a baseline reading was taken (approximately 20 minutes) and the data averaged. Compound was administered intravenously (either bolus injection of approximately 5 seconds or infusion of 15 minutes duration), and data were recorded every 1 minute for 60 minutes post compound administration. Data are calculated as either the peak change in heart rate or mean arterial pressure or are calculated as the area under the curve for changes in heart rate or blood pressure versus time. Data are expressed as mean + SEM. A one-tailed Student's paired t-test is used for statistical comparison to baseline values and considered significant at p<0.05. The SIP effects on the rat cardiovascular system are described in Sugiyama, A., N.N. Aye, Y. Yatomi, Y. Ozaki, K. Hashimoto 2000 Effects of Sphingosine- 1 -Phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system. Jpn. J. Pharmacol. 82: 338-342, hereby incoφorated by reference in its entirety.
Measurement of Mouse Acute Toxicity
A single mouse is dosed intravenously (tail vein) with 0.1 ml of test compound dissolved in a non-toxic vehicle and is observed for signs of toxicity. Severe signs may include death, seizure, paralysis or unconciousness. Milder signs are also noted and may include ataxia, labored breathing, ruffling or reduced activity relative to normal. Upon noting signs, the dosing solution is diluted in the same vehicle. The diluted dose is administered in the same fashion to a second mouse and is likewise observed for signs. The process is repeated until a dose is reached that produces no signs. This is considered the estimated no-effect level. An additional mouse is dosed at this level to confirm the absence of signs.
Assessment of Lymphopenia
Compounds are administered as described in Measurement of Mouse Acute Toxicity and lymphopenia is assessed in mice at three hours post dose as follows. After rendering a mouse unconscious by CO2 to effect, the chest is opened,
0.5 ml of blood is withdrawn via direct cardiac puncture, blood is immediately stabilized with EDTA and hematology is evaluated using a clinical hematology autoanalyzer calibrated for performing murine differential counts (H2000, CARESIDE, Culver City CA). Reduction in lymphocytes by test treatment is established by comparison of hematological parameters of three mice versus three vehicle treated mice. The dose used for this evaluation is determined by tolerability using a modification of the dilution method above. For this puφose, no-effect is desirable, mild effects are acceptable and severely toxic doses are serially diluted to levels that produce only mild effects. Example of Non-selective and Selective SlPi Edgl Agonists
To illustrate the utility of selective SlPi Edgl agonists, the activity of 2 compounds in GTPgS binding assays using human SlPl/Edgl and SlP3 Edg3 receptors and mouse acute toxicity and lymphopenia assays conducted as described above are shown. Example 2 is a non-selective potent agonist of SlPi/Edgl and SlP3/Edg3 that is highly toxic to mice at doses greater than 0.1 mg/kg, and induces immunosuppression as measured by lymphopenia at 0.1 mg/kg. Example 77 is a selective agonist of SlPχ/Edgl that induces lymphopenia at 10 mg/kg without apparent toxicity.
Figure imgf000163_0001
EXAMPLE 2 EXAMPLE 77
Compound SlPχ SIP3 IV dose Toxicity Lymphocytes*
EC50 (nM) EC50 (nM) (mg/k§)
Example 2 1.5 6.0 Lethal NE^ A A
0.25 severe NE
0.1 mild to severe 65
Example 8.4 >10000 none 38
77
* % reduction
** NE = not evaluable
A further embodiment of the invention encompasses a method of identifying a candidate compound which is an agonist of the SlPi/Edgl receptor that is selective over the SlP3/Edg3 receptor, wherein said candidate compound possesses a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 f°r tne SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said candidate compound possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35S-GTPγS binding assay,
with the proviso that the candidate compound does not fall within formula A:
Figure imgf000165_0001
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Ci_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Cι_4 alkyl or haloCι_4 alkyl;
each R2 is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCi-4alkyl, O-haloCi-4alkyl or hydroxy Ci-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4~i4alkyl and C4_i4alkenyl, comprising:
(1) providing a first receptor preparation comprising:
(a) a recombinant cell expressing the SlPi/Edgl receptor or a functional equivalent of the S IPi/Edgl receptor capable of binding to sphingosine- 1- phosphate ("SlP"); or
(b) a membrane preparation of a recombinant cell in accordance with subsection (l)(a);
(2) providing a second receptor preparation comprising:
(a) a recombinant cell expressing the SlP3/Edg3 receptor or a functional equivalent of the SlP3/Εdg3 receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or
(b) a membrane preparation of a recombinant cell in accordance with subsection (2)(a);
(3) separately contacting said cells or membrane preparations with the candidate compound; and
(4) determining whether the candidate compound binds to and activates the
SlPi/Edgl and SlP3/Edg3 receptors by measuring the level of a signal generated from the interaction of the candidate compound with each receptor, thereby indicating whether the candidate compound is an agonist of the S IPi/Edgl receptor that is selective over the SlP3/Edg3 receptor.
For puφoses of this Specification, any pathway that is activated by the SlPi/Edgl and/or SlP3/Edg3 receptors upon contact with an agonist can result in a detectable signal indicating that the receptor has been activated. Activation of the receptor by an agonist, for example, can be identified by an increase in the concentration of a relevant second messenger influenced by the receptor within cells expressing the receptor (an increase that would not be observed in cells not contacted by a receptor agonist). Those of skill in the art can readily identify an assay suitable for detecting an increase in the level of an intracellular second messenger or a detectable extracellular signal indicative of receptor activation. The signal's primary puφose is to detect (either directly or indirectly) the activation and signaling of the receptor. The signal can be either a component of the pathway or responsive to the presence or functioning of a component of the pathway. In accordance with this description, therefore, the signal can be responsive to an intracellular event which is part of the biochemical cascade initiated by receptor activation or responsive to an extracellular event such as pH changes that occur upon receptor activation. The signal can, thus, be detected by outward characteristics or by a molecule present within or administered to the cells that responds to the signal. One class of molecules that respond to intracellular changes includes those that act on changes in calcium concentration (e.g., aequorin (a jellyfish protein)) which acts on the substrate coelenterazine. Other molecules in that class include calcium chelators with fluorescence capabilities, such as FURA-2, indo-1, Fluo-3, and Fluo-4 The level of cAMP is another signal that is measured. This can be measured, for instance, byradio-immuno or protein binding assays (e.g., using Flashplates or a scintillation proximity assay). The changes in cAMP can also be determining by measuring the activity of the enzyme, adenylyl cyclase. cAMP assays are described in the art, see, e.g., Jakajima et al, 1992 J. Biol. Chem. 247:2437-2442; Tigyi et al, 1996 J. Neurochem. 66:549-558. Alternative assays disclosed in the art measure changes in inositol 1,4,5 -triphosphate levels (see, e.g., Tigyi et al, 1996 J. Neurochem. 66:537- 548); CF ion efflux (see, e.g., Postma et al, 1996 EMBO J. 15:63-72; and Watsky, 1995 Am. J. Physiol. 269:C1385-C1393); or, as provided in examples above, changes in intracellular Ca2+ levels (see also, Tigyi et al, 1996 J. Neurochem. 66:537-548. In the illustrated examples of the instant invention, binding of 35S-GTPγS to G proteins coupled to receptors is detected. This has been described in the art in the following references:
Milligan, 1988, Journal 255:1-13
Stanton and Beer, 1997, Journal 320:267-275
It is appreciated by those skilled in the art that the dose of the candidate compound contacted to said cells or membranes expressing each receptor will affect the signal generated in the assay. A positive and greater signal at the SlPl/Edgl receptor over the S lP3/Edg3 receptor at an equivalent dose will indicate a compound that is an agonist of the SlPl/Edgl receptor that is selective over the SlP3/Edg3 receptor. An "equivalent dose" means a substantially equal amount of the compounds and is well understood by artisans skilled in the art. However, the present invention is meant to include identifying the compounds using any dose as long as one skilled in the art is determining whether the candidate compounds are agonists of the SlPi/Edgl receptor that is selective over the SlP3/Εdg3 receptor.
For puφoses of this Specification, the following terms have the indicated meanin ΛgtJsu:
"SIP" means sphingosine 1-phosphate.
"Functional equivalents" are defined herein as receptors which may not possess the exact amino acid sequence due to alternative splicing, deletions, mutations, or additions, but retain the biological activity of the SlPl/Edgl or SlP3/73dg3 receptor (e.g., binding of sphingosine 1-phosphate and transduction of signals through Gi, Gq, or G12 1 heterotrimeric G proteins). Minor changes in the sequence are known in the art not to change the functionality of the receptors. See for example the following, which are hereby incoφorated by reference in their entirety:
Truncation of C-terminus of Edgl:
(Liu et al., 1999, Journal 10:1179-90.) (Watterson et al, 2002, Journal 277:5767-5777.)
Site Directed Mutagenesis of Edgl (Patrill et al., 2000, Journal 275:39379-84.)
An embodiment of the invention encompasses the method of the present invention wherein the method further comprises conducting the method in the presence of labeled or unlabeled SIP, di-hydro SIP or a ligand for the SlPl/Edgl and/or S lP3/Edg3 receptor; provided that if a ligand is utilized that is specific for either the SlPl/Edgl or SlP3/Edg3 receptor, the receptor ligand utilized in the first receptor preparation is a ligand of the SlPl/Edgl receptor and the ligand utilized in the second receptor preparation is a ligand of the SlP3 Edg3 receptor; and provided, further, that the method would additionally comprise measuring the level of a signal generated from the interaction of the SIP, di-hydro SIP or ligand; wherein a compound that effects a reduction of the signal from the interaction of the S IP, di- hydro S IP or ligand, with the receptor and activates the S IPl Edgl receptor at a greater level than that obtained at the SlP3 Edg3 receptor is a selective agonist of the SlPl/Edgl receptor.
Another embodiment of the invention encompasses the method of the present invention wherein the signal indicates extracellular pH changes caused by receptor activation.
Another embodiment of the invention encompasses the method of the present invention wherein the signal indicates levels of cAMP present within the cell.
Another embodiment of the invention encompasses the method of the present invention wherein the signal indicates adenylate cyclase accumulation. Another embodiment of the invention encompasses the method of the present invention wherein the signal indicates Ca+ flux.
Another embodiment of the invention encompasses the method of the present invention wherein the candidate compound has a selectivity for the SlP Edgl receptor over the SlP3/Εdg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the S lP3 Edg3 receptor as evaluated in the 35s~GTPγS binding assay.
Another embodiment of the invention encompasses the method of the present invention wherein the candidate compound has a selectivity for the SlP /Edgl receptor over the SlP3 Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s~GTPγS binding assay.
Another embodiment of the invention encompasses the method of the present invention wherem the candidate compound has a selectivity for the SlPl Edgl receptor over the SlP3/Εdg3 receptor of at least 500 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s~GTPγS binding assay.
Another embodiment of the invention encompasses the method of the present invention wherein the candidate compound has a selectivity for the SlPi Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the S IPi Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
Another embodiment of the invention encompasses the method of the present invention wherein the candidate compound possesses an EC50 for binding to the SlPi/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay.
The invention further encompasses a method of identifying a candidate compound which is an agonist of the SlPi/Edgl receptor that is selective over the SlP3/Edg3 receptor, wherein said candidate compound possesses a selectivity for the SlPl Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said candidate compound possesses an EC50 for binding to the SlPi Edgl receptor of 10 nM or less as evaluated by the 35s-GTPγS binding assay, comprising:
(1) providing a first receptor preparation comprising:
(a) a recombinant cell expressing the SlPl/Edgl receptor or a functional equivalent of the SlPl/Edgl receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or
(b) a membrane preparation of a recombinant cell in accordance with subsection (l)(a);
(2) providing a second receptor preparation comprising: (a) a recombinant cell expressing the SlP3/Edg3 receptor or a functional equivalent of the S lP3/Edg3 receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or (b) a membrane preparation of a recombinant cell in accordance with subsection (2)(a);
(3) separately contacting said cells or membrane preparations with the candidate compound; and (4) determining whether the candidate compound binds to and activates the SlPl/Edgl and SlP3/Εdg3 receptors by measuring the level of a signal generated from the interaction of the candidate compound with each receptor, thereby indicating whether the candidate compound is an agonist of the S IPi/Edgl receptor that is selective over the S lP3/Edg3 receptor.
Within this embodiment is encompassed the above method wherein the method further comprises conducting the method in the presence of labeled or unlabeled SIP, di-hydro SIP or a ligand for the SlPl/Edgl and/or SlP3/Edg3 receptor; provided that if a ligand is utilized that is specific for either the SlPl/Edgl or SlP3/Edg3 receptor, the receptor ligand utilized in the first receptor preparation is a ligand of the SlPl Edgl receptor and the ligand utilized in the second receptor preparation is a ligand of the SlP3/Edg 3 receptor; and provided, further, that the method would additionally comprise measuring the level of a signal generated from the interaction of the S IP, di-hydro S IP or ligand; wherein a compound that effects a reduction of the signal from the interaction of the SIP, di-hydro SIP or ligand, with the receptor and activates the SlPl Edgl receptor at a greater level than that obtained at the SlP3/Edg3 receptor is a selective agonist of the SlPl/Edgl receptor.
Also within this embodiment is encompassed the above method wherein the signal indicates extracellular pH changes caused by receptor activation.
Also within this embodiment is encompassed the above method wherein the signal indicates levels of cAMP present within the cell.
Also within this embodiment is encompassed the above method wherein the signal indicates adenylate cyclase accumulation. Also within this embodiment is encompassed the above method wherein the signal indicates Ca+ flux.
Also within this embodiment is encompassed the above method wherein the candidate compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the candidate compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s~
GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the candidate compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Εdg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the S1PR3/Εdg3 receptor as evaluated in the
35s-GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the candidate compound has a selectivity for the S IPi/Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay.
REFERENCES:
Liu, CH., S. Thangada, M.J. Lee, J.R. Van Briocklyn, S. Spiegel, and T. Hla. 1999.
Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG Mol. Biol. Cell. 10:1179-90.
Milligan, G. 1988. Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins. Biochem. J.
255:1-13.
Parrill, A.L., D. Wang, D.L. Bautista, J.R. Van. Brooklyn, Z. Lorincz, D.J. Fischer, D.L. Baker, K. Liliom, S. Spiegel, and G. Tigyi. 2000. Identification of Edgl receptor residues that recognize sphingosine 1. phosphate. /. Biol. Chem.
275:39379-84. Stanton, J.A., and M.S. Beer. 1997. Characterisation of a cloned human
Figure imgf000172_0001
receptor cell line using [35s]GTPγS binding. Euro. J. Pharm. 320:267-275. Watterson, K.R., E. Johnston, C. Chalmers, A. Pronin, S.J. Cook, J.L. Benovic, and T.M. Palmer. 2002. Dual regulation of EDG1/S1P1 receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2. J. Biol. Chem. 277:5767-5777.
RESPIRATORY DISEASES
An embodiment of the invention encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S IPl/Edgl receptor over the S 1PR3/Εdg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPl/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000173_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCι_4 alkyl; Rla is H, OH, Ci-4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Cι_4 alkyl or haloCι_4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4alkyl, O-haloCι_4alkyl or hydroxyCι_4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4~i4alkyl and C4_i4alkenyl.
Within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Εdg3 receptor as evaluated in the 35s-
GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S lP3/Εdg3 receptor as evaluated in the 35s-
GTPγS binding assay.
The invention also encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 10 nM or less as evaluated by the 35s-GTPγS binding assay.
Within this embodiment is encompassed the above method wherein the compound possesses an EC50 for binding to the SlPi/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the S IPi/Edgl receptor over the S lP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 5s-
GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPl Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-
GTPγS binding assay. Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi Edgl receptor over the SlP3/Edg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the S1PR3 Edg3 receptor as evaluated in the
35s-GTPγS binding assay.
Also within this embodiment is encompassed the above method wherein the compound has a selectivity for the SlPi/Edgl receptor over the S 1PR3 Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Εdg3 receptor as evaluated in the 5s-
GTPγS binding assay.
The invention also encompasses any of the above embodiments wherein the respiratory disease or condition is selected from the group consisting of: asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, infant respiratory distress syndrome, cough, eosinophilic granuloma, respiratory syncytial virus bronchiolitis, bronchiectasis, idiopathic pulmonary fibrosis, acute lung injury and bronchiolitis obliterans organizing pneumonia. Another embodiment of the invention encompasses any of the above embodiments further comprising concomitantly or sequentially administering one or more agents selected from the group consisting of: a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, an M2/M3 antagonist, phosphodiesterase 4 inhibitor, calcium activated chloride channel 1 agonist, a corticosteroid, an HI receptor antagonist, a beta 2 adrenoreceptor agonist and a prostaglandin D2 antagonist. These compounds are well known in the art.
The invention also encompasses a method of modulating airway function in a mammalian patient in need thereof comprising administering to said patient a compound which is an agonist of the SlPl/Edgl receptor in an amount effective for modulating airway function, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3 Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000177_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Ci-4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci-4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci-4 alkyl and haloCι_4 alkyl,
R3 is H, OH, halo, Cι_4al yl, OCι_4alkyl, O-haloCi-4alkyl or hydroxyCι_4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl. The invention also encompasses a method of reducing or preventing the activation of the SlPl/Edgl receptor in a mammalian patient in need thereof comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for reducing or preventing the activation of SlPl EDGl receptor, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000178_0001
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Ci-4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups; Rib represents H, OH, Cι_4 alkyl or haloCi_4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci_4 alkyl and haloCι_4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCi-4alkyl, O-haloCι_4alkyl orhydroxyCι_4alkyl,
Y is selected from the group consisting of: -CHfe-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
The invention also encompasses a method of inhibiting an infiltration of a lymphocyte into a respiratory tissue in a mammalian patient in need thereof by promoting a sequestration of the lymphocyte in a lymph node thereby preventing release of a pro-inflammatory mediator in the respiratory tissue comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for modulating airway function, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000180_0001
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci-4 alkyl or haloCι_4 alkyl;
each R is independently selected from the group consisting of: H, Ci_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Ci-4alkyl, OCi-4alkyl, O-haloCi-4alkyl or hydroxyCi-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O>, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4-l4alkyl and C4_i4alkenyl.

Claims

WHAT IS CLAIMED IS:
1. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl Edgl receptor over the S1PR3 Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000181_0001
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Ci_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Ci_4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups; Rib represents H, OH, Ci-4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCi-4alkyl, O-haloCι_4alkyl or hydroxyCι_4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
2. The method according to Claim 1 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
3. The method according to Claim 2 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Εdg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
4. The method according to Claim 3 wherein the compound has a selectivity for the SlPl Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
5. The method according to Claim 4 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
6. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S IPi/Edgl receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the S lP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 10 nM or less as evaluated by the 35s-GTPγS binding assay.
7. The method according to Claim 6 wherein the compound possesses an EC50 for binding to the SlPi/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay.
8. The method according to Claim 6 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPi Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
9. The method according to Claim 8 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Εdg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
10. The method according to Claim 9 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Εdg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the S IPl/Edgl receptor to the EC50 for the S1PR3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
11. The method according to Claim 10 wherein the compound has a selectivity for the SlPl Edgl receptor over the S1PR3/Εdg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
12. The method according to Claim 1 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cinhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.
13. The method according to Claim 1 wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft- versus-host disease.
14. The method according to Claim 1 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hypeφroliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, sebonhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, heφetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Bane syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic pixφura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia- reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and , hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cinhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cinhosis, alcoholic cinhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.
15. The method according to Claim 1 wherein the immunoregulatory abnormality is multiple sclerosis.
16. The method according to Claim 1 wherein the immunoregulatory abnormality is rheumatoid arthritis.
17. The method according to Claim 1 wherein the immunoregulatory abnormality is systemic lupus erythematosus.
18. The method according to Claim 1 wherein the immunoregulatory abnormality is psoriasis.
19. The method according to Claim 1 wherein the immunoregulatory abnormality is rejection of transplanted organ or tissue.
20. The method according to Claim 1 wherein the immunoregulatory abnormality is inflammatory bowel disease.
21. The method according to Claim 1 wherein the immunoregulatory abnormality is a malignancy of Iymphoid origin.
22. The method according to Claim 21 wherein the immunoregulatory abnormality is acute and chronic lymphocytic leukemias and lymphomas.
23. A pharmaceutical composition comprised of a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating an immunoregulatory abnormality, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPl/Edgl receptor of 100 nM or less as evaluated by the
35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000187_0001
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Ci-4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci-4 alkyl or haloCι.4 alkyl;
each R is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Ci^al yl, OCi_4alkyl, O-haloCi-4alkyl or hydroxyCι_4alkyl, Y is selected from the group consisting of: -CEfc-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl,
in combination with a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprised of a compound which is an agonist of the S IPi Edgl receptor in an amount effective for treating an immunoregulatory abnormality, wherein said compound possesses a selectivity for the S IPl/Edgl receptor over the S 1PR3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3 Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 10 nM or less as evaluated by the
35S-GTPγS binding assay, in combination with a pharmaceutically acceptable carrier.
25. A method of identifying a candidate compound which is an agonist of the SlPi Edgl receptor that is selective over the SlP3/Edg3 receptor, wherein said candidate compound possesses a selectivity for the SlPi/Edgl receptor over the SlP3 Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35S-GTPγS binding assay and wherein said candidate compound possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s- GTPγS binding assay,
with the proviso that the candidate compound does not fall within formula A:
Figure imgf000189_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Cι_4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Ci-4 alkyl and haloCι_4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4al yl, O-haloCi-4alkyl or hydroxyCi-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4-i4alkenyl, compnsmg:
(1) providing a first receptor preparation comprising:
(a) a recombinant cell expressing the SlPl/Edgl receptor or a functional equivalent of the SlP Edgl receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or
(b) a membrane preparation of a recombinant cell in accordance with subsection (l)(a);
(2) providing a second receptor preparation comprismg:
(a) a recombinant cell expressing the SlP3/Edg3 receptor or a functional equivalent of the SlP3 Edg3 receptor capable of binding to sphingosine- 1- phosphate ("SlP"); or
(b) a membrane preparation of a recombinant cell in accordance with subsection (2)(a);
(3) separately contacting said cells or membrane preparations with the candidate compound; and
(4) determining whether the candidate compound binds to and activates the
SlPi/Edgl and SlP3/Ed3 receptors by measuring the level of a signal generated from the interaction of the candidate compound with each receptor, thereby indicating whether the candidate compound is an agonist of the SlPi/Edgl receptor that is selective over the SlP3/Edg3 receptor.
26. A method in accordance with claim 25 wherein the method further comprises conducting the method in the presence of labeled or unlabeled SIP, di- hydro SIP or a ligand for the SlPl/Edgl and/or SlP3/Edg3 receptor; provided that if a ligand is utilized that is specific for either the SlPl/Edgl or SlP3/Edg3 receptor, the receptor ligand utilized in the first receptor preparation is a ligand of the S IP 1/Edgl receptor and the ligand utilized in the second receptor preparation is a ligand of the SlP3/Edg3 receptor; and provided, further, that the method would additionally comprise measuring the level of a signal generated from the interaction of the SIP, di- hydro SIP or ligand; wherein a compound that effects a reduction of the signal from the interaction of the SIP, di-hydro SIP or ligand, with the receptor and activates the SlPl Edgl receptor at a greater level than that obtained at the SlP3 Edg3 receptor is a selective agonist of the SlPl/Edgl receptor.
27. A method in accordance with claim 25 wherein the signal indicates extracellular pH changes caused by receptor activation.
28. A method in accordance with claim 25 wherein the signal indicates levels of cAMP present within the cell.
29. A method in accordance with claim 25 wherein the signal indicates adenylate cyclase accumulation.
30. A method in accordance with claim 25 wherein the signal indicates Ca+ flux.
31. The method according to Claim 25 wherein the candidate compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPi Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
32. The method according to Claim 31 wherein the candidate compound has a selectivity for the SlPl Edgl receptor over the SlP3 Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
33. The method according to Claim 32 wherein the candidate compound has a selectivity for the SlPl/Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35S-GTPγS binding assay.
34. The method according to Claim 33 wherein the candidate compound has a selectivity for the SlPl Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
35. The method according to Claim 25 wherein the candidate compound possesses an EC50 for binding to the SlPi/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay.
36. A method of identifying a candidate compound which is an agonist of the SlPi/Edgl receptor that is selective over the SlP3/Edg3 receptor, wherein said candidate compound possesses a selectivity for the SlPl/Edgl receptor over the SlP3/Εdg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SlPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said candidate compound possesses an EC50 for binding to the SlPl/Edgl receptor of 10 nM or less as evaluated by the 35s- GTPγS binding assay, comprising:
(1) providing a first receptor preparation comprising: (a) a recombinant cell expressing the SlPl/Edgl receptor or a functional equivalent of the SlPl/Edgl receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or (b) a membrane preparation of a recombinant cell in accordance with subsection (l)(a);
(2) providing a second receptor preparation comprising:
(a) a recombinant cell expressing the SlP3/Edg3 receptor or a functional equivalent of the SlP3/Edg3 receptor capable of binding to sphingosine- 1- phosphate ("SIP"); or (b) a membrane preparation of a recombinant cell in accordance with subsection (2)(a); (3) separately contacting said cells or membrane preparations with the candidate compound; and
(4) determining whether the candidate compound binds to and activates the S IPi/Edgl and S lP3/Εd3 receptors by measuring the level of a signal generated from the interaction of the candidate compound with each receptor, thereby indicating whether the candidate compound is an agonist of the SlPi/Edgl receptor that is selective over the SlP3/Edg3 receptor.
37. A method in accordance with claim 36 wherein the method further comprises conducting the method in the presence of labeled or unlabeled SIP, di- hydro SIP or a ligand for the SlPl/Edgl and/or SlP3 Edg3 receptor; provided that if a ligand is utilized that is specific for either the SlPl/Edgl or SlP3/Edg3 receptor, the receptor ligand utilized in the first receptor preparation is a ligand of the SlPl Edgl receptor and the ligand utilized in the second receptor preparation is a ligand of the SlP3/Edg 3 receptor; and provided, further, that the method would additionally comprise measuring the level of a signal generated from the interaction of the SIP, di- hydro SIP or ligand; wherein a compound that effects a reduction of the signal from the interaction of the SIP, di-hydro SIP or ligand, with the receptor and activates the SIPl/Edgl receptor at a greater level than that obtained at the SlP3 Edg3 receptor is a selective agonist of the SIPl/Edgl receptor.
38. A method in accordance with claim 36 wherein the signal indicates extracellular pH changes caused by receptor activation.
39. A method in accordance with claim 36 wherein the signal indicates levels of cAMP present within the cell.
40. A method in accordance with claim 36 wherein the signal indicates adenylate cyclase accumulation.
41. A method in accordance with claim 36 wherein the signal indicates Ca+ flux.
42. The method according to Claim 36 wherein the candidate compound has a selectivity for the SIPl Edgl receptor over the SlP3 Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SIPl Edgl receptor to the EC50 for the S lP3/Εdg3 receptor as evaluated in the 35s-GTPγS binding assay.
43. The method according to Claim 42 wherein the candidate compound has a selectivity for the SlPi Edgl receptor over the SlP3/Εdg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
44. The method according to Claim 43 wherein the candidate compound has a selectivity for the SlPi Edgl receptor over the SlP3/Edg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the S 1PR3/Εdg3 receptor as evaluated in the 35s-GTPγS binding assay.
45. The method according to Claim 44 wherein the candidate compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the S lP3/Εdg3 receptor as evaluated in the 35s-GTPγS binding assay.
46. A method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SIPl Edgl receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the SIPl/Edgl receptor over the S1PR3/Εdg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SIPl/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000195_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Cι_4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Ci-4alkyl, OCi-4alkyl, O-haloCι_4alkyl or hydroxyCi-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
47. The method according to Claim 46 wherein the compound has a selectivity for the SlPi Edgl receptor over the SlP3 Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the SIPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
48. The method according to Claim 47 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SlPi Edgl receptor to the EC50 for the SlP3/Εdg3 receptor as evaluated in the 35s-GTPγS binding assay.
49. The method according to Claim 48 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 500 fold as measured by the ratio of EC50 for the SlPi Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
50. The method according to Claim 49 wherein the compound has a selectivity for the SlPi/Edgl receptor over the SlP3/Edg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
51. A method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the SIPl/Edgl receptor over the SlP3/Edg3 receptor of at least 100 fold as measured by the ratio of EC50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 10 nM or less as evaluated by the 35s-GTPγS binding assay.
52. The method according to Claim 51 wherein the compound possesses an EC50 for binding to the SlPi/Edgl receptor of 1 nM or less as evaluated by the 35s-GTPγS binding assay.
53. The method according to Claim 52 wherein the compound has a selectivity for the SIPl/Edgl receptor over the SlP3 Edg3 receptor of at least 200 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
54. The method according to Claim 53 wherein the compound has a selectivity for the SlPi Edgl receptor over the SlP3 Edg3 receptor of at least 500 fold as measured by the ratio of EC 50 for the S IPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
55. The method according to Claim 54 wherein the compound has a selectivity for the SIPl/Edgl receptor over the SlP3/Edg3 receptor of at least 1000 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the S1PR3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
56. The method according to Claim 55 wherein the compound has a selectivity for the SlPi/Edgl receptor over the S1PR3/Εdg3 receptor of at least 2000 fold as measured by the ratio of EC50 for the SIPl/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay.
57. The method according to Claim 46 wherein the respiratory disease or condition is selected from the group consisting of: asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, infant respiratory distress syndrome, cough, eosinophilic granuloma, respiratory syncytial virus bronchiolitis, bronchiectasis, idiopathic pulmonary fibrosis, acute lung injury and bronchiolitis obliterans organizing pneumonia.
58. The method according to Claim 46 further comprising concomitantly or sequentially administering one or more agents selected from the group consisting of: a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, an M2/M3 antagonist, phosphodiesterase 4 inhibitor, calcium activated chloride channel 1 agonist, a corticosteroid, an HI receptor antagonist, a beta 2 adrenoreceptor agonist and a prostaglandin D2 antagonist.
59. A method of modulating airway function in a mammalian patient in need thereof comprising administering to said patient a compound which is an agonist of the S IPi/Edgl receptor in an amount effective for modulating airway function, wherein said compound possesses a selectivity for the SlPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3 Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SIPl Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within fonnula A:
Figure imgf000198_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Ci_4alkyl or haloCi-4 alkyl; Rla is H, OH, Ci-4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Ci-4 alkyl or haloCi-4 alkyl;
each R is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4alkyl, O-haloCι_4alkyl or hydroxyCi-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
60. A method of reducing or preventing the activation of the SlPl/Edgl receptor in a mammalian patient in need thereof comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for reducing or preventing the activation of SlPl/Edgl receptor, wherein said compound possesses a selectivity for the SIPl/Edgl receptor over the S1PR3/Edg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s- GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SlPi/Edgl receptor of 100 nM or less as evaluated by the 35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000200_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2, optionally substituted with 1-4 halo groups;
Rl is H, Cι_4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCι_4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups;
Rib represents H, OH, Cι_4 alkyl or haloCi-4 alkyl;
each R2 is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCi-4alkyl, O-haloCι_4alkyl or hydroxyCi-4alkyl,
Y is selected from the group consisting of: -CH2-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
61. A method of inhibiting an infiltration of a lymphocyte into a respiratory tissue in a mammalian patient in need thereof by promoting a sequestration of the lymphocyte in a lymph node thereby preventing release of a pro-inflammatory mediator in the respiratory tissue comprising administering to said patient a compound which is an agonist of the SlPi/Edgl receptor in an amount effective for modulating airway function, wherein said compound possesses a selectivity for the SIPl/Edgl receptor over the S1PR3/Εdg3 receptor of at least 20 fold as measured by the ratio of EC50 for the SlPi/Edgl receptor to the EC50 for the SlP3/Edg3 receptor as evaluated in the 35s-GTPγS binding assay and wherein said compound possesses an EC50 for binding to the SIPl/Edgl receptor of 100 nM or less as evaluated by the
35s-GTPγS binding assay,
with the proviso that the compound does not fall within formula A:
Figure imgf000201_0001
A
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is O, S, NRl or (CH2)l-2> optionally substituted with 1-4 halo groups;
Rl is H, Ci-4alkyl or haloCi-4 alkyl;
Rla is H, OH, Cι_4alkyl, or OCi-4 alkyl, the alkyl and alkyl portions being optionally substituted with 1-3 halo groups; Rib represents H, OH, Ci-4 alkyl or haloCι_4 alkyl;
each R2 is independently selected from the group consisting of: H, Cι_4 alkyl and haloCi-4 alkyl,
R3 is H, OH, halo, Cι_4alkyl, OCι_4alkyl, O-haloCi_4alkyl or hydroxyCι_4alkyl,
Y is selected from the group consisting of: -CHfc-, -C(O)-, -CH(OH)-, -C(=NOH)-, O and S, and
R4 is selected from the group consisting of: C4_i4alkyl and C4_i4alkenyl.
PCT/US2003/001120 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists WO2003061567A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002472680A CA2472680A1 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists
EP20030731917 EP1469863A2 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists
AU2003216054A AU2003216054B2 (en) 2002-01-18 2003-01-14 Selective S1P1/Edg1 receptor agonists
US10/501,176 US20050070506A1 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34999102P 2002-01-18 2002-01-18
US60/349,991 2002-01-18
US36256602P 2002-03-07 2002-03-07
US60/362,566 2002-03-07
US38293302P 2002-05-23 2002-05-23
US60/382,933 2002-05-23

Publications (2)

Publication Number Publication Date
WO2003061567A2 true WO2003061567A2 (en) 2003-07-31
WO2003061567A3 WO2003061567A3 (en) 2003-12-24

Family

ID=27617582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001120 WO2003061567A2 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists

Country Status (5)

Country Link
US (1) US20050070506A1 (en)
EP (1) EP1469863A2 (en)
AU (1) AU2003216054B2 (en)
CA (1) CA2472680A1 (en)
WO (1) WO2003061567A2 (en)

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074297A1 (en) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
WO2005020882A3 (en) * 2003-08-29 2005-04-21 Ono Pharmaceutical Co Compound capable of binding s1p receptor and pharmaceutical use thereof
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
JP2005527494A (en) * 2002-01-18 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド N- (benzyl) aminoalkylcarboxylic acid compounds, phosphinic acid compounds, phosphonic acid compounds and tetrazoles as Edg receptor agonists
WO2006020951A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2006043149A2 (en) * 2004-10-22 2006-04-27 Bioprojet Novel dicarboxylic acid derivatives
WO2006058316A1 (en) 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
WO2006064757A1 (en) 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
WO2006086361A2 (en) * 2005-02-08 2006-08-17 Novartis Ag ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS
WO2006094705A1 (en) * 2005-03-04 2006-09-14 Novartis Ag Ophthalmic uses of s1p receptor modulators
WO2006128055A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7199113B2 (en) 1998-09-25 2007-04-03 Jin-An Jiao Pharmaceutically active compounds and methods of use thereof
US7220734B2 (en) 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
EP1804793A2 (en) * 2004-10-22 2007-07-11 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2008018427A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008018447A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
WO2008023783A1 (en) * 2006-08-25 2008-02-28 Asahi Kasei Pharma Corporation Amine compound
JP2008507477A (en) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ Polypeptide extension tag
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
JP2008545767A (en) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト Polycyclic oxadiazoles or isoxazoles and their use as SIP receptor ligands
EP2008650A2 (en) 2003-04-08 2008-12-31 Novartis AG Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
DE102007036068A1 (en) 2007-08-01 2009-02-05 Wacker Chemie Ag Process for the preparation of alkylmethoxymethyltrimethylsilanylmethylamines
JP2009523165A (en) * 2006-01-11 2009-06-18 アクテリオン ファーマシューティカルズ リミテッド Novel thiophene derivatives as S1P1 / EDG1 receptor agonists
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2010010127A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010014943A2 (en) * 2008-08-01 2010-02-04 Bioxiness Pharmaceutics, Inc. Methionine analogs and methods of using same
AU2004253473B2 (en) * 2003-06-24 2010-03-04 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7678820B2 (en) 2006-04-03 2010-03-16 Astellas Pharma Inc. Hetero compound
US7754896B2 (en) * 2004-01-21 2010-07-13 Novartis Ag Indol-alanine derivatives as selective S1P4-agonists
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
US7786173B2 (en) 2006-11-21 2010-08-31 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
US7790707B2 (en) 2006-03-21 2010-09-07 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7855193B2 (en) 2005-11-23 2010-12-21 Epix Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
WO2011017578A1 (en) 2009-08-07 2011-02-10 Bristol-Myers Squibb Company Sphingosine-1-phosphate receptor agonists
US7915315B2 (en) 2006-11-21 2011-03-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2011066179A1 (en) * 2009-11-24 2011-06-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
US7964649B2 (en) 2006-11-21 2011-06-21 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
EP2351560A1 (en) 2005-01-04 2011-08-03 Novartis AG Treatment Of HCV infections with FTY720
US8008286B2 (en) 2006-01-27 2011-08-30 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
US8080542B2 (en) 2007-09-20 2011-12-20 Amgen, Inc. S1P receptor modulating compounds and use thereof
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
US8173710B2 (en) 2006-02-09 2012-05-08 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
US8193378B2 (en) 2008-12-05 2012-06-05 Astellas Pharma Inc. 2H-chromene compound and derivative thereof
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
EP2583720A1 (en) 2008-07-15 2013-04-24 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
US8507685B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
US8513418B2 (en) 2011-04-18 2013-08-20 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8519006B2 (en) 2003-12-19 2013-08-27 Novartis Ag Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases
US8541582B2 (en) 2011-04-14 2013-09-24 Allergan, Inc. Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
WO2014130752A2 (en) 2013-02-21 2014-08-28 Bristol-Myers Squibb Company Bicyclic compounds
WO2014138075A1 (en) * 2013-03-07 2014-09-12 Allergan, Inc. Phosphonic acid compounds as sphingosine-1-phosphate receptor modulators
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US9085581B2 (en) 2010-03-03 2015-07-21 Arena Pharmaceuticals, Inc. Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof
WO2016028959A1 (en) 2014-08-20 2016-02-25 Bristol-Myers Squibb Company Substituted bicyclic compounds
US9340527B2 (en) 2011-02-07 2016-05-17 Biogen Ma Inc. S1P modulating agents
US9572824B2 (en) 2009-08-05 2017-02-21 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
US10251867B2 (en) 2008-03-17 2019-04-09 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective S1P1 receptor agonist
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
CN110724723A (en) * 2019-10-08 2020-01-24 南京信息工程大学 Method for measuring and calculating half-effect concentration of pollutant ecotoxicity effect
CN111803484A (en) * 2020-09-04 2020-10-23 郑州大学 Application of otilonium bromide in preparing antitumor drugs
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
JP2022517316A (en) * 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド Leukotriene synthesis inhibitor
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311786A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
WO2007132307A1 (en) * 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2012071212A2 (en) * 2010-11-23 2012-05-31 Allergan, Inc. Novel phosphonic acids as s1p receptor modulators
US9884087B1 (en) 2013-05-03 2018-02-06 Chan Soon-Shiong Nanthealth Foundation Compositions and methods of improved wound healing
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
IL294071A (en) * 2020-01-06 2022-08-01 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437165B1 (en) * 2000-08-31 2002-08-20 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (en) * 1992-10-21 1998-12-01 고우야 마사시 2-amino-1,3-propanediol compound and immunosuppressant
US5585476A (en) * 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
JPH09278888A (en) * 1996-04-16 1997-10-28 Idemitsu Petrochem Co Ltd Apparatus for producing polyarylene sulfide and production of polyarylene sulfide using the same
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
US6130067A (en) * 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
US6323333B1 (en) * 1999-04-05 2001-11-27 Smithkline Beecham Corporation Mouse EDG1
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437165B1 (en) * 2000-08-31 2002-08-20 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Cited By (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199113B2 (en) 1998-09-25 2007-04-03 Jin-An Jiao Pharmaceutically active compounds and methods of use thereof
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
JP2005527494A (en) * 2002-01-18 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド N- (benzyl) aminoalkylcarboxylic acid compounds, phosphinic acid compounds, phosphonic acid compounds and tetrazoles as Edg receptor agonists
US7560477B2 (en) 2002-07-30 2009-07-14 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
US7763752B2 (en) 2002-09-19 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppresive agents
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
US7220734B2 (en) 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
EP1602660A1 (en) * 2003-02-18 2005-12-07 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
AU2004213297B2 (en) * 2003-02-18 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
EP2172472A2 (en) * 2003-02-18 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
EP2172472A3 (en) * 2003-02-18 2010-06-30 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
US7456157B2 (en) 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
EP1602660A4 (en) * 2003-02-18 2008-03-19 Kyorin Seiyaku Kk Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
US7759326B2 (en) 2003-02-18 2010-07-20 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof, and modulator of S1P receptor
WO2004074297A1 (en) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
DE202004021680U1 (en) 2003-04-08 2010-04-22 Novartis Ag Solid pharmaceutical composition
EP2769713A1 (en) 2003-04-08 2014-08-27 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
EP2316431A1 (en) 2003-04-08 2011-05-04 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
EP2008650A2 (en) 2003-04-08 2008-12-31 Novartis AG Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol
US8324283B2 (en) 2003-04-08 2012-12-04 Novartis Ag Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
US7462629B2 (en) 2003-05-19 2008-12-09 Irm Llc Immunosuppressant compounds and compositions
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
AU2004253473B2 (en) * 2003-06-24 2010-03-04 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US9101575B2 (en) 2003-06-24 2015-08-11 The University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7838562B2 (en) 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
EP1643983B1 (en) * 2003-06-24 2010-05-05 The University of Connecticut Methods of inhibiting vascular permeability and apoptosis
WO2005020882A3 (en) * 2003-08-29 2005-04-21 Ono Pharmaceutical Co Compound capable of binding s1p receptor and pharmaceutical use thereof
KR101186386B1 (en) 2003-08-29 2012-09-26 오노 야꾸힝 고교 가부시키가이샤 Compound capable of binding s1p receptor and pharmaceutical use thereof
JP2014240432A (en) * 2003-08-29 2014-12-25 小野薬品工業株式会社 S1p receptor binding-ability possessing compound and medical use thereof
AU2004268455B2 (en) * 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US8791159B2 (en) 2003-08-29 2014-07-29 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
JP2013151528A (en) * 2003-08-29 2013-08-08 Ono Pharmaceut Co Ltd Compound capable of binding s1p receptor and pharmaceutical use thereof
EP2883865A1 (en) 2003-08-29 2015-06-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005060961A3 (en) * 2003-12-18 2006-01-05 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US8519006B2 (en) 2003-12-19 2013-08-27 Novartis Ag Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases
US7754896B2 (en) * 2004-01-21 2010-07-13 Novartis Ag Indol-alanine derivatives as selective S1P4-agonists
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US9061067B2 (en) 2004-07-08 2015-06-23 Novo Nordisk A/S Polypeptide protracting tags
JP2008507477A (en) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ Polypeptide extension tag
WO2006020951A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US7241812B2 (en) 2004-08-13 2007-07-10 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
WO2006043149A3 (en) * 2004-10-22 2006-07-13 Bioprojet Soc Civ Novel dicarboxylic acid derivatives
WO2006043149A2 (en) * 2004-10-22 2006-04-27 Bioprojet Novel dicarboxylic acid derivatives
EP1804793A2 (en) * 2004-10-22 2007-07-11 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP2008517915A (en) * 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド 2- (Aryl) azacyclylmethylcarboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
EP1804793A4 (en) * 2004-10-22 2010-03-31 Merck Sharp & Dohme 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
CN102600472A (en) * 2004-11-29 2012-07-25 诺瓦提斯公司 Dosage regimen of an s1p receptor agonist
EP2359821A1 (en) 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
WO2006058316A1 (en) 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
EP2384749A1 (en) 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
CN101068536B (en) * 2004-11-29 2012-12-05 诺瓦提斯公司 Dosage regimen of an S1P receptor agonist
US8575134B2 (en) 2004-12-13 2013-11-05 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
EP2371811A3 (en) * 2004-12-13 2011-11-30 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EP2592066A1 (en) 2004-12-13 2013-05-15 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medical use thereof
EP2371811A2 (en) 2004-12-13 2011-10-05 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EP1826197A4 (en) * 2004-12-13 2009-12-30 Ono Pharmaceutical Co Aminocarboxylic acid derivative and medicinal use thereof
WO2006064757A1 (en) 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
EP1826197A1 (en) * 2004-12-13 2007-08-29 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
US7906549B2 (en) 2004-12-13 2011-03-15 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
EP2351560A1 (en) 2005-01-04 2011-08-03 Novartis AG Treatment Of HCV infections with FTY720
WO2006086361A2 (en) * 2005-02-08 2006-08-17 Novartis Ag ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS
WO2006086361A3 (en) * 2005-02-08 2007-01-18 Novartis Ag ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
US8329676B2 (en) 2005-02-14 2012-12-11 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
AU2010202185B2 (en) * 2005-03-04 2012-06-14 Novartis Ag Ophthalmic uses of S1P receptor modulators
JP2008531632A (en) * 2005-03-04 2008-08-14 ノバルティス アクチエンゲゼルシャフト Ophthalmic use of S1P receptor modulators
EP2216019A2 (en) 2005-03-04 2010-08-11 Novartis AG Ophthalmic uses of S1P receptor modulators
WO2006094705A1 (en) * 2005-03-04 2006-09-14 Novartis Ag Ophthalmic uses of s1p receptor modulators
JP2013063991A (en) * 2005-03-04 2013-04-11 Novartis Ag Ophthalmic use of s1p receptor modulator
WO2006128055A3 (en) * 2005-05-26 2007-05-24 Metabasis Therapeutics Inc Novel phosphorus-containing thyromimetics
US10925885B2 (en) 2005-05-26 2021-02-23 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006128055A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP2008545767A (en) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト Polycyclic oxadiazoles or isoxazoles and their use as SIP receptor ligands
US7855193B2 (en) 2005-11-23 2010-12-21 Epix Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
JP2009523165A (en) * 2006-01-11 2009-06-18 アクテリオン ファーマシューティカルズ リミテッド Novel thiophene derivatives as S1P1 / EDG1 receptor agonists
US8008286B2 (en) 2006-01-27 2011-08-30 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
US8173710B2 (en) 2006-02-09 2012-05-08 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US7790707B2 (en) 2006-03-21 2010-09-07 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US7678820B2 (en) 2006-04-03 2010-03-16 Astellas Pharma Inc. Hetero compound
US7951825B2 (en) 2006-04-03 2011-05-31 Astellas Pharma Inc. Hetero compound
WO2008018447A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
WO2008018427A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008023783A1 (en) * 2006-08-25 2008-02-28 Asahi Kasei Pharma Corporation Amine compound
US7786173B2 (en) 2006-11-21 2010-08-31 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
US7915315B2 (en) 2006-11-21 2011-03-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US7964649B2 (en) 2006-11-21 2011-06-21 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US7847117B2 (en) 2007-08-01 2010-12-07 Wacker Chemie Ag Process for preparing alkyl(methoxymethyl)trimethylsilanylmethylamines
DE102007036068A1 (en) 2007-08-01 2009-02-05 Wacker Chemie Ag Process for the preparation of alkylmethoxymethyltrimethylsilanylmethylamines
EP2050754A1 (en) 2007-08-01 2009-04-22 Wacker Chemie AG Method for manufacturing alkyl-methoxymethyl-trimethylsilanylmethyl amines
US8080542B2 (en) 2007-09-20 2011-12-20 Amgen, Inc. S1P receptor modulating compounds and use thereof
US10251867B2 (en) 2008-03-17 2019-04-09 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective S1P1 receptor agonist
US10660880B2 (en) 2008-03-17 2020-05-26 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 agonist
US8735387B2 (en) 2008-07-15 2014-05-27 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
EP2583720A1 (en) 2008-07-15 2013-04-24 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
US9522133B2 (en) 2008-07-23 2016-12-20 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US9149459B2 (en) 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
AU2009273259B2 (en) * 2008-07-23 2013-05-02 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
US9126932B2 (en) 2008-07-23 2015-09-08 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2010010127A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EP2695615A3 (en) * 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8580859B2 (en) 2008-08-01 2013-11-12 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
WO2010014943A2 (en) * 2008-08-01 2010-02-04 Bioxiness Pharmaceutics, Inc. Methionine analogs and methods of using same
WO2010014943A3 (en) * 2008-08-01 2011-01-13 Bioxiness Pharmaceutics, Inc. Methionine analogs and methods of using same
US9695119B2 (en) 2008-08-01 2017-07-04 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US9108969B2 (en) 2008-08-27 2015-08-18 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8193378B2 (en) 2008-12-05 2012-06-05 Astellas Pharma Inc. 2H-chromene compound and derivative thereof
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
US9572824B2 (en) 2009-08-05 2017-02-21 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
US10166250B2 (en) 2009-08-05 2019-01-01 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
US9827258B2 (en) 2009-08-05 2017-11-28 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
WO2011017578A1 (en) 2009-08-07 2011-02-10 Bristol-Myers Squibb Company Sphingosine-1-phosphate receptor agonists
EP2597089A1 (en) 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
EP2592071A1 (en) 2009-10-29 2013-05-15 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
CN102712618B (en) * 2009-11-24 2014-11-26 阿勒根公司 Novel compounds as receptor modulators with therapeutic utility
CN102712618A (en) * 2009-11-24 2012-10-03 阿勒根公司 Novel compounds as receptor modulators with therapeutic utility
WO2011066179A1 (en) * 2009-11-24 2011-06-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
JP2013512243A (en) * 2009-11-24 2013-04-11 アラーガン インコーポレイテッド Novel compounds as receptor modulators with therapeutic utility
US8440644B2 (en) 2009-11-24 2013-05-14 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
US8703745B1 (en) 2009-11-24 2014-04-22 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
US8828973B2 (en) 2009-11-24 2014-09-09 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
US8653062B2 (en) 2009-11-24 2014-02-18 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
US11149292B2 (en) 2010-01-27 2021-10-19 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US9447041B2 (en) 2010-01-27 2016-09-20 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
US11674163B2 (en) 2010-01-27 2023-06-13 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US9175320B2 (en) 2010-01-27 2015-11-03 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
US9085581B2 (en) 2010-03-03 2015-07-21 Arena Pharmaceuticals, Inc. Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
US10406144B2 (en) 2011-02-07 2019-09-10 Biogen Ma Inc. SIP modulating agents
US9808449B2 (en) 2011-02-07 2017-11-07 Biogen Ma Inc. S1P modulating agents
US9340527B2 (en) 2011-02-07 2016-05-17 Biogen Ma Inc. S1P modulating agents
US10894040B2 (en) 2011-02-07 2021-01-19 Biogen Ma Inc. S1P modulating agents
US10034869B2 (en) 2011-02-07 2018-07-31 Biogen Ma Inc. S1P modulating agents
US8541582B2 (en) 2011-04-14 2013-09-24 Allergan, Inc. Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
JP2014511878A (en) * 2011-04-14 2014-05-19 アラーガン インコーポレイテッド Phenylbicyclic methylamine derivatives as sphingosine-1-phosphate receptor modulators
US8946195B2 (en) 2011-04-14 2015-02-03 Allergan, Inc. Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8716267B2 (en) 2011-04-14 2014-05-06 Allergan, Inc. Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
US8507685B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8673892B2 (en) 2011-04-14 2014-03-18 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8653050B2 (en) 2011-04-14 2014-02-18 Allergan, Inc. Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8658634B2 (en) 2011-04-14 2014-02-25 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
US8513418B2 (en) 2011-04-18 2013-08-20 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US8658623B2 (en) 2011-04-18 2014-02-25 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
WO2014130752A2 (en) 2013-02-21 2014-08-28 Bristol-Myers Squibb Company Bicyclic compounds
WO2014138075A1 (en) * 2013-03-07 2014-09-12 Allergan, Inc. Phosphonic acid compounds as sphingosine-1-phosphate receptor modulators
WO2016028959A1 (en) 2014-08-20 2016-02-25 Bristol-Myers Squibb Company Substituted bicyclic compounds
US11896578B2 (en) 2015-01-06 2024-02-13 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
US10676435B2 (en) 2015-06-22 2020-06-09 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11091435B2 (en) 2015-06-22 2021-08-17 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Alkylphenyl compounds
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
JP2022517316A (en) * 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド Leukotriene synthesis inhibitor
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
CN110724723B (en) * 2019-10-08 2023-04-07 南京信息工程大学 Method for measuring and calculating semi-effective concentration of pollutant ecotoxicity effect
CN110724723A (en) * 2019-10-08 2020-01-24 南京信息工程大学 Method for measuring and calculating half-effect concentration of pollutant ecotoxicity effect
CN111803484B (en) * 2020-09-04 2021-08-17 郑州大学 Application of otilonium bromide in preparing antitumor drugs
CN111803484A (en) * 2020-09-04 2020-10-23 郑州大学 Application of otilonium bromide in preparing antitumor drugs

Also Published As

Publication number Publication date
WO2003061567A3 (en) 2003-12-24
CA2472680A1 (en) 2003-07-31
US20050070506A1 (en) 2005-03-31
EP1469863A2 (en) 2004-10-27
AU2003216054B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
EP1469863A2 (en) Selective s1p1/edg1 receptor agonists
AU2003216054A1 (en) Selective S1P1/Edg1 receptor agonists
US7351725B2 (en) N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
US7479504B2 (en) Edg receptor agonists
US20040058894A1 (en) Selective S1P1/Edg1 receptor agonists
AU2003297232B2 (en) 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
AU2003207567A1 (en) Edg receptor agonists
US20060252741A1 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
US20070043014A1 (en) 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
AU2003202994A1 (en) N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
EP1549640A2 (en) 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
EP1482896A2 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003216054

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2472680

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10501176

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003731917

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003731917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP